{
    "questions": [
        {
            "body": "Is Hirschsprung disease a mendelian or a multifactorial disorder?", 
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:10487", 
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006627", 
                "http://www.disease-ontology.org/api/metadata/DOID:11372", 
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020412"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15829955", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15617541", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12239580", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8896569", 
                "http://www.ncbi.nlm.nih.gov/pubmed/6650562", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20598273", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21995290", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23001136"
            ], 
            "exact_answer": "Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease.The inheritance of Hirschsprung disease is generally consistent with sex-modified multifactorial inheritance with a lower threshold of expression in malesHirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genesThe non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative modelIn the etiology of Hirschsprung disease various genes play a role; these are: RET, EDNRB, GDNF, EDN3 and SOX10, NTN3, ECE1, Mutations in these genes may result in dominant, recessive or multifactorial patterns of inheritance.Furthermore, mutations in the RET gene are responsible for approximately half of the familial and some sporadic cases, strongly suggesting, on the one hand, the importance of non-coding variations and, on the other hand, that additional genes involved in the development of the enteric nervous system still await their discovery", 
            "id": "55031181e9bde69634000014", 
            "ideal_answer": [
                "Coding sequence mutations in RET, GDNF, EDNRB, EDN3, and SOX10 are involved in the development of Hirschsprung disease. The majority of these genes was shown to be related to Mendelian syndromic forms of Hirschsprung's disease, whereas the non-Mendelian inheritance of sporadic non-syndromic Hirschsprung disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model."
            ], 
            "ranked": [
                "Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease.", 
                "The inheritance of Hirschsprung disease is generally consistent with sex-modified multifactorial inheritance with a lower threshold of expression in males", 
                "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes", 
                "The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model", 
                "In the etiology of Hirschsprung disease various genes play a role; these are: RET, EDNRB, GDNF, EDN3 and SOX10, NTN3, ECE1, Mutations in these genes may result in dominant, recessive or multifactorial patterns of inheritance.", 
                "Furthermore, mutations in the RET gene are responsible for approximately half of the familial and some sporadic cases, strongly suggesting, on the one hand, the importance of non-coding variations and, on the other hand, that additional genes involved in the development of the enteric nervous system still await their discovery", 
                "In this study, we review the identification of genes and loci involved in the non-syndromic common form and syndromic Mendelian forms of Hirschsprung's disease.", 
                "Therefore, HSCR has become a model for a complex oligo-/polygenic disorder in which the relationship between different genes creating a non-mendelian inheritance pattern still remains to be elucidated", 
                "Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability.", 
                "On the basis of a skewed sex-ratio (M/F = 4/1) and a risk to relatives much higher than the incidence in the general population, HSCR has long been regarded as a sex-modified multifactorial disorder"
            ], 
            "snippets": [
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 131, 
                    "offsetInEndSection": 358, 
                    "sentences": [
                        {
                            "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes", 
                            "tokens": [
                                "Hirschsprung", 
                                "disease", 
                                "(", 
                                "HSCR", 
                                ")", 
                                "is", 
                                "a", 
                                "multifactorial", 
                                ",", 
                                "non-mendelian", 
                                "disorder", 
                                "in", 
                                "which", 
                                "rare", 
                                "high-penetrance", 
                                "coding", 
                                "sequence", 
                                "mutations", 
                                "in", 
                                "the", 
                                "receptor", 
                                "tyrosine", 
                                "kinase", 
                                "RET", 
                                "contribute", 
                                "to", 
                                "risk", 
                                "in", 
                                "combination", 
                                "with", 
                                "mutations", 
                                "at", 
                                "other", 
                                "genes"
                            ]
                        }
                    ], 
                    "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15617541", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 554, 
                    "offsetInEndSection": 992, 
                    "sentences": [
                        {
                            "text": "In this study, we review the identification of genes and loci involved in the non-syndromic common form and syndromic Mendelian forms of Hirschsprung's disease.", 
                            "tokens": [
                                "In", 
                                "this", 
                                "study", 
                                ",", 
                                "we", 
                                "review", 
                                "the", 
                                "identification", 
                                "of", 
                                "genes", 
                                "and", 
                                "loci", 
                                "involved", 
                                "in", 
                                "the", 
                                "non-syndromic", 
                                "common", 
                                "form", 
                                "and", 
                                "syndromic", 
                                "Mendelian", 
                                "forms", 
                                "of", 
                                "Hirschsprung", 
                                "'s", 
                                "disease", 
                                "."
                            ]
                        }, 
                        {
                            "text": "The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease.", 
                            "tokens": [
                                "The", 
                                "majority", 
                                "of", 
                                "the", 
                                "identified", 
                                "genes", 
                                "are", 
                                "related", 
                                "to", 
                                "Mendelian", 
                                "syndromic", 
                                "forms", 
                                "of", 
                                "Hirschsprung", 
                                "'s", 
                                "disease", 
                                "."
                            ]
                        }, 
                        {
                            "text": "The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model", 
                            "tokens": [
                                "The", 
                                "non-Mendelian", 
                                "inheritance", 
                                "of", 
                                "sporadic", 
                                "non-syndromic", 
                                "Hirschsprung", 
                                "'s", 
                                "disease", 
                                "proved", 
                                "to", 
                                "be", 
                                "complex", 
                                ";", 
                                "involvement", 
                                "of", 
                                "multiple", 
                                "loci", 
                                "was", 
                                "demonstrated", 
                                "in", 
                                "a", 
                                "multiplicative", 
                                "model"
                            ]
                        }
                    ], 
                    "text": "In this study, we review the identification of genes and loci involved in the non-syndromic common form and syndromic Mendelian forms of Hirschsprung's disease. The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease. The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12239580", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 397, 
                    "offsetInEndSection": 939, 
                    "sentences": [
                        {
                            "text": "Coding sequence mutations in e.g.", 
                            "tokens": [
                                "Coding", 
                                "sequence", 
                                "mutations", 
                                "in", 
                                "e.g", 
                                "."
                            ]
                        }, 
                        {
                            "text": "RET, GDNF, EDNRB, EDN3, and SOX10 lead to long-segment (L-HSCR) as well as syndromic HSCR but fail to explain the transmission of the much more common short-segment form (S-HSCR).", 
                            "tokens": [
                                "RET", 
                                ",", 
                                "GDNF", 
                                ",", 
                                "EDNRB", 
                                ",", 
                                "EDN3", 
                                ",", 
                                "and", 
                                "SOX10", 
                                "lead", 
                                "to", 
                                "long-segment", 
                                "(", 
                                "L-HSCR", 
                                ")", 
                                "as", 
                                "well", 
                                "as", 
                                "syndromic", 
                                "HSCR", 
                                "but", 
                                "fail", 
                                "to", 
                                "explain", 
                                "the", 
                                "transmission", 
                                "of", 
                                "the", 
                                "much", 
                                "more", 
                                "common", 
                                "short-segment", 
                                "form", 
                                "(", 
                                "S-HSCR", 
                                ")", 
                                "."
                            ]
                        }, 
                        {
                            "text": "Furthermore, mutations in the RET gene are responsible for approximately half of the familial and some sporadic cases, strongly suggesting, on the one hand, the importance of non-coding variations and, on the other hand, that additional genes involved in the development of the enteric nervous system still await their discovery", 
                            "tokens": [
                                "Furthermore", 
                                ",", 
                                "mutations", 
                                "in", 
                                "the", 
                                "RET", 
                                "gene", 
                                "are", 
                                "responsible", 
                                "for", 
                                "approximately", 
                                "half", 
                                "of", 
                                "the", 
                                "familial", 
                                "and", 
                                "some", 
                                "sporadic", 
                                "cases", 
                                ",", 
                                "strongly", 
                                "suggesting", 
                                ",", 
                                "on", 
                                "the", 
                                "one", 
                                "hand", 
                                ",", 
                                "the", 
                                "importance", 
                                "of", 
                                "non-coding", 
                                "variations", 
                                "and", 
                                ",", 
                                "on", 
                                "the", 
                                "other", 
                                "hand", 
                                ",", 
                                "that", 
                                "additional", 
                                "genes", 
                                "involved", 
                                "in", 
                                "the", 
                                "development", 
                                "of", 
                                "the", 
                                "enteric", 
                                "nervous", 
                                "system", 
                                "still", 
                                "await", 
                                "their", 
                                "discovery"
                            ]
                        }
                    ], 
                    "text": "Coding sequence mutations in e.g. RET, GDNF, EDNRB, EDN3, and SOX10 lead to long-segment (L-HSCR) as well as syndromic HSCR but fail to explain the transmission of the much more common short-segment form (S-HSCR). Furthermore, mutations in the RET gene are responsible for approximately half of the familial and some sporadic cases, strongly suggesting, on the one hand, the importance of non-coding variations and, on the other hand, that additional genes involved in the development of the enteric nervous system still await their discovery"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12239580", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 941, 
                    "offsetInEndSection": 1279, 
                    "sentences": [
                        {
                            "text": "For almost all of the identified HSCR genes incomplete penetrance of the HSCR phenotype has been reported, probably due to modifier loci.", 
                            "tokens": [
                                "For", 
                                "almost", 
                                "all", 
                                "of", 
                                "the", 
                                "identified", 
                                "HSCR", 
                                "genes", 
                                "incomplete", 
                                "penetrance", 
                                "of", 
                                "the", 
                                "HSCR", 
                                "phenotype", 
                                "has", 
                                "been", 
                                "reported", 
                                ",", 
                                "probably", 
                                "due", 
                                "to", 
                                "modifier", 
                                "loci", 
                                "."
                            ]
                        }, 
                        {
                            "text": "Therefore, HSCR has become a model for a complex oligo-/polygenic disorder in which the relationship between different genes creating a non-mendelian inheritance pattern still remains to be elucidated", 
                            "tokens": [
                                "Therefore", 
                                ",", 
                                "HSCR", 
                                "has", 
                                "become", 
                                "a", 
                                "model", 
                                "for", 
                                "a", 
                                "complex", 
                                "oligo-/polygenic", 
                                "disorder", 
                                "in", 
                                "which", 
                                "the", 
                                "relationship", 
                                "between", 
                                "different", 
                                "genes", 
                                "creating", 
                                "a", 
                                "non-mendelian", 
                                "inheritance", 
                                "pattern", 
                                "still", 
                                "remains", 
                                "to", 
                                "be", 
                                "elucidated"
                            ]
                        }
                    ], 
                    "text": "For almost all of the identified HSCR genes incomplete penetrance of the HSCR phenotype has been reported, probably due to modifier loci. Therefore, HSCR has become a model for a complex oligo-/polygenic disorder in which the relationship between different genes creating a non-mendelian inheritance pattern still remains to be elucidated"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 129, 
                    "offsetInEndSection": 358, 
                    "sentences": [
                        {
                            "text": " Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes.", 
                            "tokens": [
                                "Hirschsprung", 
                                "disease", 
                                "(", 
                                "HSCR", 
                                ")", 
                                "is", 
                                "a", 
                                "multifactorial", 
                                ",", 
                                "non-mendelian", 
                                "disorder", 
                                "in", 
                                "which", 
                                "rare", 
                                "high-penetrance", 
                                "coding", 
                                "sequence", 
                                "mutations", 
                                "in", 
                                "the", 
                                "receptor", 
                                "tyrosine", 
                                "kinase", 
                                "RET", 
                                "contribute", 
                                "to", 
                                "risk", 
                                "in", 
                                "combination", 
                                "with", 
                                "mutations", 
                                "at", 
                                "other", 
                                "genes", 
                                "."
                            ]
                        }
                    ], 
                    "text": " Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6650562", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 851, 
                    "offsetInEndSection": 1007, 
                    "sentences": [
                        {
                            "text": " The inheritance of Hirschsprung disease is generally consistent with sex-modified multifactorial inheritance with a lower threshold of expression in males.", 
                            "tokens": [
                                "The", 
                                "inheritance", 
                                "of", 
                                "Hirschsprung", 
                                "disease", 
                                "is", 
                                "generally", 
                                "consistent", 
                                "with", 
                                "sex-modified", 
                                "multifactorial", 
                                "inheritance", 
                                "with", 
                                "a", 
                                "lower", 
                                "threshold", 
                                "of", 
                                "expression", 
                                "in", 
                                "males", 
                                "."
                            ]
                        }
                    ], 
                    "text": " The inheritance of Hirschsprung disease is generally consistent with sex-modified multifactorial inheritance with a lower threshold of expression in males."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 131, 
                    "offsetInEndSection": 359, 
                    "sentences": [
                        {
                            "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes.", 
                            "tokens": [
                                "Hirschsprung", 
                                "disease", 
                                "(", 
                                "HSCR", 
                                ")", 
                                "is", 
                                "a", 
                                "multifactorial", 
                                ",", 
                                "non-mendelian", 
                                "disorder", 
                                "in", 
                                "which", 
                                "rare", 
                                "high-penetrance", 
                                "coding", 
                                "sequence", 
                                "mutations", 
                                "in", 
                                "the", 
                                "receptor", 
                                "tyrosine", 
                                "kinase", 
                                "RET", 
                                "contribute", 
                                "to", 
                                "risk", 
                                "in", 
                                "combination", 
                                "with", 
                                "mutations", 
                                "at", 
                                "other", 
                                "genes", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20598273", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 131, 
                    "sentences": [
                        {
                            "text": "Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability.", 
                            "tokens": [
                                "Differential", 
                                "contributions", 
                                "of", 
                                "rare", 
                                "and", 
                                "common", 
                                ",", 
                                "coding", 
                                "and", 
                                "noncoding", 
                                "Ret", 
                                "mutations", 
                                "to", 
                                "multifactorial", 
                                "Hirschsprung", 
                                "disease", 
                                "liability", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21995290", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 210, 
                    "sentences": [
                        {
                            "text": "BACKGROUND: RET is the major gene associated to Hirschsprung disease (HSCR) with differential contributions of its rare and common, coding and noncoding mutations to the multifactorial nature of this pathology.", 
                            "tokens": [
                                "BACKGROUND", 
                                ":", 
                                "RET", 
                                "is", 
                                "the", 
                                "major", 
                                "gene", 
                                "associated", 
                                "to", 
                                "Hirschsprung", 
                                "disease", 
                                "(", 
                                "HSCR", 
                                ")", 
                                "with", 
                                "differential", 
                                "contributions", 
                                "of", 
                                "its", 
                                "rare", 
                                "and", 
                                "common", 
                                ",", 
                                "coding", 
                                "and", 
                                "noncoding", 
                                "mutations", 
                                "to", 
                                "the", 
                                "multifactorial", 
                                "nature", 
                                "of", 
                                "this", 
                                "pathology", 
                                "."
                            ]
                        }
                    ], 
                    "text": "BACKGROUND: RET is the major gene associated to Hirschsprung disease (HSCR) with differential contributions of its rare and common, coding and noncoding mutations to the multifactorial nature of this pathology."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 131, 
                    "offsetInEndSection": 358, 
                    "sentences": [
                        {
                            "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes", 
                            "tokens": [
                                "Hirschsprung", 
                                "disease", 
                                "(", 
                                "HSCR", 
                                ")", 
                                "is", 
                                "a", 
                                "multifactorial", 
                                ",", 
                                "non-mendelian", 
                                "disorder", 
                                "in", 
                                "which", 
                                "rare", 
                                "high-penetrance", 
                                "coding", 
                                "sequence", 
                                "mutations", 
                                "in", 
                                "the", 
                                "receptor", 
                                "tyrosine", 
                                "kinase", 
                                "RET", 
                                "contribute", 
                                "to", 
                                "risk", 
                                "in", 
                                "combination", 
                                "with", 
                                "mutations", 
                                "at", 
                                "other", 
                                "genes"
                            ]
                        }
                    ], 
                    "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15617541", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 554, 
                    "offsetInEndSection": 992, 
                    "sentences": [
                        {
                            "text": "In this study, we review the identification of genes and loci involved in the non-syndromic common form and syndromic Mendelian forms of Hirschsprung's disease.", 
                            "tokens": [
                                "In", 
                                "this", 
                                "study", 
                                ",", 
                                "we", 
                                "review", 
                                "the", 
                                "identification", 
                                "of", 
                                "genes", 
                                "and", 
                                "loci", 
                                "involved", 
                                "in", 
                                "the", 
                                "non-syndromic", 
                                "common", 
                                "form", 
                                "and", 
                                "syndromic", 
                                "Mendelian", 
                                "forms", 
                                "of", 
                                "Hirschsprung", 
                                "'s", 
                                "disease", 
                                "."
                            ]
                        }, 
                        {
                            "text": "The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease.", 
                            "tokens": [
                                "The", 
                                "majority", 
                                "of", 
                                "the", 
                                "identified", 
                                "genes", 
                                "are", 
                                "related", 
                                "to", 
                                "Mendelian", 
                                "syndromic", 
                                "forms", 
                                "of", 
                                "Hirschsprung", 
                                "'s", 
                                "disease", 
                                "."
                            ]
                        }, 
                        {
                            "text": "The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model", 
                            "tokens": [
                                "The", 
                                "non-Mendelian", 
                                "inheritance", 
                                "of", 
                                "sporadic", 
                                "non-syndromic", 
                                "Hirschsprung", 
                                "'s", 
                                "disease", 
                                "proved", 
                                "to", 
                                "be", 
                                "complex", 
                                ";", 
                                "involvement", 
                                "of", 
                                "multiple", 
                                "loci", 
                                "was", 
                                "demonstrated", 
                                "in", 
                                "a", 
                                "multiplicative", 
                                "model"
                            ]
                        }
                    ], 
                    "text": "In this study, we review the identification of genes and loci involved in the non-syndromic common form and syndromic Mendelian forms of Hirschsprung's disease. The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease. The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 131, 
                    "offsetInEndSection": 359, 
                    "sentences": [
                        {
                            "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes.", 
                            "tokens": [
                                "Hirschsprung", 
                                "disease", 
                                "(", 
                                "HSCR", 
                                ")", 
                                "is", 
                                "a", 
                                "multifactorial", 
                                ",", 
                                "non-mendelian", 
                                "disorder", 
                                "in", 
                                "which", 
                                "rare", 
                                "high-penetrance", 
                                "coding", 
                                "sequence", 
                                "mutations", 
                                "in", 
                                "the", 
                                "receptor", 
                                "tyrosine", 
                                "kinase", 
                                "RET", 
                                "contribute", 
                                "to", 
                                "risk", 
                                "in", 
                                "combination", 
                                "with", 
                                "mutations", 
                                "at", 
                                "other", 
                                "genes", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15858239", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 151, 
                    "offsetInEndSection": 376, 
                    "sentences": [
                        {
                            "text": "In the etiology of Hirschsprung disease various genes play a role; these are: RET, EDNRB, GDNF, EDN3 and SOX10, NTN3, ECE1, Mutations in these genes may result in dominant, recessive or multifactorial patterns of inheritance.", 
                            "tokens": [
                                "In", 
                                "the", 
                                "etiology", 
                                "of", 
                                "Hirschsprung", 
                                "disease", 
                                "various", 
                                "genes", 
                                "play", 
                                "a", 
                                "role", 
                                ";", 
                                "these", 
                                "are", 
                                ":", 
                                "RET", 
                                ",", 
                                "EDNRB", 
                                ",", 
                                "GDNF", 
                                ",", 
                                "EDN3", 
                                "and", 
                                "SOX10", 
                                ",", 
                                "NTN3", 
                                ",", 
                                "ECE1", 
                                ",", 
                                "Mutations", 
                                "in", 
                                "these", 
                                "genes", 
                                "may", 
                                "result", 
                                "in", 
                                "dominant", 
                                ",", 
                                "recessive", 
                                "or", 
                                "multifactorial", 
                                "patterns", 
                                "of", 
                                "inheritance", 
                                "."
                            ]
                        }
                    ], 
                    "text": "In the etiology of Hirschsprung disease various genes play a role; these are: RET, EDNRB, GDNF, EDN3 and SOX10, NTN3, ECE1, Mutations in these genes may result in dominant, recessive or multifactorial patterns of inheritance."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 131, 
                    "offsetInEndSection": 358, 
                    "sentences": [
                        {
                            "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes", 
                            "tokens": [
                                "Hirschsprung", 
                                "disease", 
                                "(", 
                                "HSCR", 
                                ")", 
                                "is", 
                                "a", 
                                "multifactorial", 
                                ",", 
                                "non-mendelian", 
                                "disorder", 
                                "in", 
                                "which", 
                                "rare", 
                                "high-penetrance", 
                                "coding", 
                                "sequence", 
                                "mutations", 
                                "in", 
                                "the", 
                                "receptor", 
                                "tyrosine", 
                                "kinase", 
                                "RET", 
                                "contribute", 
                                "to", 
                                "risk", 
                                "in", 
                                "combination", 
                                "with", 
                                "mutations", 
                                "at", 
                                "other", 
                                "genes"
                            ]
                        }
                    ], 
                    "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 131, 
                    "offsetInEndSection": 358, 
                    "sentences": [
                        {
                            "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes", 
                            "tokens": [
                                "Hirschsprung", 
                                "disease", 
                                "(", 
                                "HSCR", 
                                ")", 
                                "is", 
                                "a", 
                                "multifactorial", 
                                ",", 
                                "non-mendelian", 
                                "disorder", 
                                "in", 
                                "which", 
                                "rare", 
                                "high-penetrance", 
                                "coding", 
                                "sequence", 
                                "mutations", 
                                "in", 
                                "the", 
                                "receptor", 
                                "tyrosine", 
                                "kinase", 
                                "RET", 
                                "contribute", 
                                "to", 
                                "risk", 
                                "in", 
                                "combination", 
                                "with", 
                                "mutations", 
                                "at", 
                                "other", 
                                "genes"
                            ]
                        }
                    ], 
                    "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 83, 
                    "sentences": [
                        {
                            "text": "Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease.", 
                            "tokens": [
                                "Chromosomal", 
                                "and", 
                                "related", 
                                "Mendelian", 
                                "syndromes", 
                                "associated", 
                                "with", 
                                "Hirschsprung", 
                                "'s", 
                                "disease", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15617541", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 715, 
                    "offsetInEndSection": 818, 
                    "sentences": [
                        {
                            "text": "The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease", 
                            "tokens": [
                                "The", 
                                "majority", 
                                "of", 
                                "the", 
                                "identified", 
                                "genes", 
                                "are", 
                                "related", 
                                "to", 
                                "Mendelian", 
                                "syndromic", 
                                "forms", 
                                "of", 
                                "Hirschsprung", 
                                "'s", 
                                "disease"
                            ]
                        }
                    ], 
                    "text": "The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 131, 
                    "offsetInEndSection": 358, 
                    "sentences": [
                        {
                            "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes", 
                            "tokens": [
                                "Hirschsprung", 
                                "disease", 
                                "(", 
                                "HSCR", 
                                ")", 
                                "is", 
                                "a", 
                                "multifactorial", 
                                ",", 
                                "non-mendelian", 
                                "disorder", 
                                "in", 
                                "which", 
                                "rare", 
                                "high-penetrance", 
                                "coding", 
                                "sequence", 
                                "mutations", 
                                "in", 
                                "the", 
                                "receptor", 
                                "tyrosine", 
                                "kinase", 
                                "RET", 
                                "contribute", 
                                "to", 
                                "risk", 
                                "in", 
                                "combination", 
                                "with", 
                                "mutations", 
                                "at", 
                                "other", 
                                "genes"
                            ]
                        }
                    ], 
                    "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15858239", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 151, 
                    "offsetInEndSection": 375, 
                    "sentences": [
                        {
                            "text": "In the etiology of Hirschsprung disease various genes play a role; these are: RET, EDNRB, GDNF, EDN3 and SOX10, NTN3, ECE1, Mutations in these genes may result in dominant, recessive or multifactorial patterns of inheritance", 
                            "tokens": [
                                "In", 
                                "the", 
                                "etiology", 
                                "of", 
                                "Hirschsprung", 
                                "disease", 
                                "various", 
                                "genes", 
                                "play", 
                                "a", 
                                "role", 
                                ";", 
                                "these", 
                                "are", 
                                ":", 
                                "RET", 
                                ",", 
                                "EDNRB", 
                                ",", 
                                "GDNF", 
                                ",", 
                                "EDN3", 
                                "and", 
                                "SOX10", 
                                ",", 
                                "NTN3", 
                                ",", 
                                "ECE1", 
                                ",", 
                                "Mutations", 
                                "in", 
                                "these", 
                                "genes", 
                                "may", 
                                "result", 
                                "in", 
                                "dominant", 
                                ",", 
                                "recessive", 
                                "or", 
                                "multifactorial", 
                                "patterns", 
                                "of", 
                                "inheritance"
                            ]
                        }
                    ], 
                    "text": "In the etiology of Hirschsprung disease various genes play a role; these are: RET, EDNRB, GDNF, EDN3 and SOX10, NTN3, ECE1, Mutations in these genes may result in dominant, recessive or multifactorial patterns of inheritance"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 83, 
                    "sentences": [
                        {
                            "text": "Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease.", 
                            "tokens": [
                                "Chromosomal", 
                                "and", 
                                "related", 
                                "Mendelian", 
                                "syndromes", 
                                "associated", 
                                "with", 
                                "Hirschsprung", 
                                "'s", 
                                "disease", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15617541", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 715, 
                    "offsetInEndSection": 818, 
                    "sentences": [
                        {
                            "text": "The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease", 
                            "tokens": [
                                "The", 
                                "majority", 
                                "of", 
                                "the", 
                                "identified", 
                                "genes", 
                                "are", 
                                "related", 
                                "to", 
                                "Mendelian", 
                                "syndromic", 
                                "forms", 
                                "of", 
                                "Hirschsprung", 
                                "'s", 
                                "disease"
                            ]
                        }
                    ], 
                    "text": "The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 131, 
                    "offsetInEndSection": 358, 
                    "sentences": [
                        {
                            "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes", 
                            "tokens": [
                                "Hirschsprung", 
                                "disease", 
                                "(", 
                                "HSCR", 
                                ")", 
                                "is", 
                                "a", 
                                "multifactorial", 
                                ",", 
                                "non-mendelian", 
                                "disorder", 
                                "in", 
                                "which", 
                                "rare", 
                                "high-penetrance", 
                                "coding", 
                                "sequence", 
                                "mutations", 
                                "in", 
                                "the", 
                                "receptor", 
                                "tyrosine", 
                                "kinase", 
                                "RET", 
                                "contribute", 
                                "to", 
                                "risk", 
                                "in", 
                                "combination", 
                                "with", 
                                "mutations", 
                                "at", 
                                "other", 
                                "genes"
                            ]
                        }
                    ], 
                    "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8896569", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 417, 
                    "offsetInEndSection": 615, 
                    "sentences": [
                        {
                            "text": "On the basis of a skewed sex-ratio (M/F = 4/1) and a risk to relatives much higher than the incidence in the general population, HSCR has long been regarded as a sex-modified multifactorial disorder", 
                            "tokens": [
                                "On", 
                                "the", 
                                "basis", 
                                "of", 
                                "a", 
                                "skewed", 
                                "sex-ratio", 
                                "(", 
                                "M/F", 
                                "=", 
                                "4/1", 
                                ")", 
                                "and", 
                                "a", 
                                "risk", 
                                "to", 
                                "relatives", 
                                "much", 
                                "higher", 
                                "than", 
                                "the", 
                                "incidence", 
                                "in", 
                                "the", 
                                "general", 
                                "population", 
                                ",", 
                                "HSCR", 
                                "has", 
                                "long", 
                                "been", 
                                "regarded", 
                                "as", 
                                "a", 
                                "sex-modified", 
                                "multifactorial", 
                                "disorder"
                            ]
                        }
                    ], 
                    "text": "On the basis of a skewed sex-ratio (M/F = 4/1) and a risk to relatives much higher than the incidence in the general population, HSCR has long been regarded as a sex-modified multifactorial disorder"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6650562", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 858, 
                    "offsetInEndSection": 1012, 
                    "sentences": [
                        {
                            "text": "The inheritance of Hirschsprung disease is generally consistent with sex-modified multifactorial inheritance with a lower threshold of expression in males", 
                            "tokens": [
                                "The", 
                                "inheritance", 
                                "of", 
                                "Hirschsprung", 
                                "disease", 
                                "is", 
                                "generally", 
                                "consistent", 
                                "with", 
                                "sex-modified", 
                                "multifactorial", 
                                "inheritance", 
                                "with", 
                                "a", 
                                "lower", 
                                "threshold", 
                                "of", 
                                "expression", 
                                "in", 
                                "males"
                            ]
                        }
                    ], 
                    "text": "The inheritance of Hirschsprung disease is generally consistent with sex-modified multifactorial inheritance with a lower threshold of expression in males"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15858239", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 151, 
                    "offsetInEndSection": 375, 
                    "sentences": [
                        {
                            "text": "In the etiology of Hirschsprung disease various genes play a role; these are: RET, EDNRB, GDNF, EDN3 and SOX10, NTN3, ECE1, Mutations in these genes may result in dominant, recessive or multifactorial patterns of inheritance", 
                            "tokens": [
                                "In", 
                                "the", 
                                "etiology", 
                                "of", 
                                "Hirschsprung", 
                                "disease", 
                                "various", 
                                "genes", 
                                "play", 
                                "a", 
                                "role", 
                                ";", 
                                "these", 
                                "are", 
                                ":", 
                                "RET", 
                                ",", 
                                "EDNRB", 
                                ",", 
                                "GDNF", 
                                ",", 
                                "EDN3", 
                                "and", 
                                "SOX10", 
                                ",", 
                                "NTN3", 
                                ",", 
                                "ECE1", 
                                ",", 
                                "Mutations", 
                                "in", 
                                "these", 
                                "genes", 
                                "may", 
                                "result", 
                                "in", 
                                "dominant", 
                                ",", 
                                "recessive", 
                                "or", 
                                "multifactorial", 
                                "patterns", 
                                "of", 
                                "inheritance"
                            ]
                        }
                    ], 
                    "text": "In the etiology of Hirschsprung disease various genes play a role; these are: RET, EDNRB, GDNF, EDN3 and SOX10, NTN3, ECE1, Mutations in these genes may result in dominant, recessive or multifactorial patterns of inheritance"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 83, 
                    "sentences": [
                        {
                            "text": "Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease.", 
                            "tokens": [
                                "Chromosomal", 
                                "and", 
                                "related", 
                                "Mendelian", 
                                "syndromes", 
                                "associated", 
                                "with", 
                                "Hirschsprung", 
                                "'s", 
                                "disease", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15617541", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 715, 
                    "offsetInEndSection": 818, 
                    "sentences": [
                        {
                            "text": "The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease", 
                            "tokens": [
                                "The", 
                                "majority", 
                                "of", 
                                "the", 
                                "identified", 
                                "genes", 
                                "are", 
                                "related", 
                                "to", 
                                "Mendelian", 
                                "syndromic", 
                                "forms", 
                                "of", 
                                "Hirschsprung", 
                                "'s", 
                                "disease"
                            ]
                        }
                    ], 
                    "text": "The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15617541", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 820, 
                    "offsetInEndSection": 992, 
                    "sentences": [
                        {
                            "text": "The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model", 
                            "tokens": [
                                "The", 
                                "non-Mendelian", 
                                "inheritance", 
                                "of", 
                                "sporadic", 
                                "non-syndromic", 
                                "Hirschsprung", 
                                "'s", 
                                "disease", 
                                "proved", 
                                "to", 
                                "be", 
                                "complex", 
                                ";", 
                                "involvement", 
                                "of", 
                                "multiple", 
                                "loci", 
                                "was", 
                                "demonstrated", 
                                "in", 
                                "a", 
                                "multiplicative", 
                                "model"
                            ]
                        }
                    ], 
                    "text": "The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 131, 
                    "offsetInEndSection": 358, 
                    "sentences": [
                        {
                            "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes", 
                            "tokens": [
                                "Hirschsprung", 
                                "disease", 
                                "(", 
                                "HSCR", 
                                ")", 
                                "is", 
                                "a", 
                                "multifactorial", 
                                ",", 
                                "non-mendelian", 
                                "disorder", 
                                "in", 
                                "which", 
                                "rare", 
                                "high-penetrance", 
                                "coding", 
                                "sequence", 
                                "mutations", 
                                "in", 
                                "the", 
                                "receptor", 
                                "tyrosine", 
                                "kinase", 
                                "RET", 
                                "contribute", 
                                "to", 
                                "risk", 
                                "in", 
                                "combination", 
                                "with", 
                                "mutations", 
                                "at", 
                                "other", 
                                "genes"
                            ]
                        }
                    ], 
                    "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 83, 
                    "sentences": [
                        {
                            "text": "Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease.", 
                            "tokens": [
                                "Chromosomal", 
                                "and", 
                                "related", 
                                "Mendelian", 
                                "syndromes", 
                                "associated", 
                                "with", 
                                "Hirschsprung", 
                                "'s", 
                                "disease", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease."
                }
            ], 
            "tokens": [
                "Is", 
                "Hirschsprung", 
                "disease", 
                "a", 
                "mendelian", 
                "or", 
                "a", 
                "multifactorial", 
                "disorder", 
                "?"
            ], 
            "triples": [], 
            "type": "summary"
        }, 
        {
            "body": "List signaling molecules (ligands) that interact with the receptor EGFR?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018773", 
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008024", 
                "http://www.uniprot.org/uniprot/EGFR_CHICK", 
                "http://www.uniprot.org/uniprot/EGFR_HUMAN", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007176", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005006", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005154", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005488", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0045741", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007175", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0042058", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007173"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24323361", 
                "http://www.ncbi.nlm.nih.gov/pubmed/24204699", 
                "http://www.ncbi.nlm.nih.gov/pubmed/24124521", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23959273", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23888072", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23821377", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23787814", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23729230", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23399900", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23382875", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23212918", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23099994", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23089711", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22260327", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22247333", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21514161"
            ], 
            "exact_answer": "the epidermal growth factor receptor (EGFR) ligands, such as epidermal growth factor (EGF) and amphiregulin (AREG).EGFR ligands based on the two affinity classes: EGF>HB-EGF>TGF-\u03b1>BTC>EPR>EPG>ARfour EGFR ligands (AR, HB-EGF, TGF-\u03b1, and EREG) EGFR and its ligand EGFAmong EGFR ligands, heparin-binding EGF-like growth factor, TGF-\u03b1 and Betacellulin (BTC) are produced in the tumor microenvironment of FDC-S at RNA level. Of the six known EGFR ligands, transforming growth factor alpha (TGF\u03b1) was expressed more highly in triple-negative breast tumors than in tumors of other subtypes.oluble amphiregulin (AR), transforming growth factor alpha (TGF\u03b1), neuregulin 2 beta, and epigen stimulate greater EGFR coupling to cell proliferation and DNA synthesis than do EGF, betacellulin, heparin-binding EGF-like growth factor, and epiregulinthe 7 known EGFR ligands (EGF, betacellulin, epiregulin, heparin-binding EGF, transforming growth factor-\u03b1 [TGF-\u03b1], amphiregulin, and epigen)", 
            "id": "55046d5ff8aee20f27000007", 
            "ideal_answer": [
                "The 7 known EGFR ligands  are: epidermal growth factor (EGF), betacellulin (BTC), epiregulin (EPR), heparin-binding EGF (HB-EGF), transforming growth factor-\u03b1 [TGF-\u03b1], amphiregulin (AREG) and epigen (EPG)."
            ], 
            "ranked": [
                "the epidermal growth factor receptor (EGFR) ligands, such as epidermal growth factor (EGF) and amphiregulin (AREG)", 
                ".", 
                "EGFR ligands based on the two affinity classes: EGF>HB-EGF>TGF-\u03b1>BTC>EPR>EPG>AR", 
                "four EGFR ligands (AR, HB-EGF, TGF-\u03b1, and EREG)", 
                " EGFR and its ligand EGF", 
                "Among EGFR ligands, heparin-binding EGF-like growth factor, TGF-\u03b1 and Betacellulin (BTC) are produced in the tumor microenvironment of FDC-S at RNA level.", 
                " Of the six known EGFR ligands, transforming growth factor alpha (TGF\u03b1) was expressed more highly in triple-negative breast tumors than in tumors of other subtypes.", 
                "oluble amphiregulin (AR), transforming growth factor alpha (TGF\u03b1), neuregulin 2 beta, and epigen stimulate greater EGFR coupling to cell proliferation and DNA synthesis than do EGF, betacellulin, heparin-binding EGF-like growth factor, and epiregulin", 
                "the 7 known EGFR ligands (EGF, betacellulin, epiregulin, heparin-binding EGF, transforming growth factor-\u03b1 [TGF-\u03b1], amphiregulin, and epigen)", 
                "In this article, however, we demonstrate that PEPD directly binds to and activates epidermal growth factor receptor (EGFR),"
            ], 
            "snippets": [
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24323361", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1085, 
                    "offsetInEndSection": 1199, 
                    "sentences": [
                        {
                            "text": "the epidermal growth factor receptor (EGFR) ligands, such as epidermal growth factor (EGF) and amphiregulin (AREG)", 
                            "tokens": [
                                "the", 
                                "epidermal", 
                                "growth", 
                                "factor", 
                                "receptor", 
                                "(", 
                                "EGFR", 
                                ")", 
                                "ligands", 
                                ",", 
                                "such", 
                                "as", 
                                "epidermal", 
                                "growth", 
                                "factor", 
                                "(", 
                                "EGF", 
                                ")", 
                                "and", 
                                "amphiregulin", 
                                "(", 
                                "AREG", 
                                ")"
                            ]
                        }
                    ], 
                    "text": "the epidermal growth factor receptor (EGFR) ligands, such as epidermal growth factor (EGF) and amphiregulin (AREG)"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24124521", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1139, 
                    "offsetInEndSection": 1247, 
                    "sentences": [
                        {
                            "text": " EGFR ligands epidermal growth factor (EGF), amphiregulin (AREG) and transforming growth factor alpha (TGF\u03b1)", 
                            "tokens": [
                                "EGFR", 
                                "ligands", 
                                "epidermal", 
                                "growth", 
                                "factor", 
                                "(", 
                                "EGF", 
                                ")", 
                                ",", 
                                "amphiregulin", 
                                "(", 
                                "AREG", 
                                ")", 
                                "and", 
                                "transforming", 
                                "growth", 
                                "factor", 
                                "alpha", 
                                "(", 
                                "TGF\u03b1", 
                                ")"
                            ]
                        }
                    ], 
                    "text": " EGFR ligands epidermal growth factor (EGF), amphiregulin (AREG) and transforming growth factor alpha (TGF\u03b1)"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23959273", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 72, 
                    "offsetInEndSection": 97, 
                    "sentences": [
                        {
                            "text": " EGFR and its ligand EGF", 
                            "tokens": [
                                "EGFR", 
                                "and", 
                                "its", 
                                "ligand", 
                                "EGF"
                            ]
                        }
                    ], 
                    "text": " EGFR and its ligand EGF "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23888072", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 903, 
                    "offsetInEndSection": 1058, 
                    "sentences": [
                        {
                            "text": "Among EGFR ligands, heparin-binding EGF-like growth factor, TGF-\u03b1 and Betacellulin (BTC) are produced in the tumor microenvironment of FDC-S at RNA level.", 
                            "tokens": [
                                "Among", 
                                "EGFR", 
                                "ligands", 
                                ",", 
                                "heparin-binding", 
                                "EGF-like", 
                                "growth", 
                                "factor", 
                                ",", 
                                "TGF-\u03b1", 
                                "and", 
                                "Betacellulin", 
                                "(", 
                                "BTC", 
                                ")", 
                                "are", 
                                "produced", 
                                "in", 
                                "the", 
                                "tumor", 
                                "microenvironment", 
                                "of", 
                                "FDC-S", 
                                "at", 
                                "RNA", 
                                "level", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Among EGFR ligands, heparin-binding EGF-like growth factor, TGF-\u03b1 and Betacellulin (BTC) are produced in the tumor microenvironment of FDC-S at RNA level. "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821377", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 322, 
                    "offsetInEndSection": 493, 
                    "sentences": [
                        {
                            "text": ".", 
                            "tokens": [
                                "."
                            ]
                        }, 
                        {
                            "text": "Plasma amphiregulin (AR), epidermal growth factor (EGF), transforming growth factor-\u03b1, and heparin binding-EGF were assessed by ELISA in 45 chemorefractory mCRC patients", 
                            "tokens": [
                                "Plasma", 
                                "amphiregulin", 
                                "(", 
                                "AR", 
                                ")", 
                                ",", 
                                "epidermal", 
                                "growth", 
                                "factor", 
                                "(", 
                                "EGF", 
                                ")", 
                                ",", 
                                "transforming", 
                                "growth", 
                                "factor-\u03b1", 
                                ",", 
                                "and", 
                                "heparin", 
                                "binding-EGF", 
                                "were", 
                                "assessed", 
                                "by", 
                                "ELISA", 
                                "in", 
                                "45", 
                                "chemorefractory", 
                                "mCRC", 
                                "patients"
                            ]
                        }
                    ], 
                    "text": ". Plasma amphiregulin (AR), epidermal growth factor (EGF), transforming growth factor-\u03b1, and heparin binding-EGF were assessed by ELISA in 45 chemorefractory mCRC patients"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23787814", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 346, 
                    "offsetInEndSection": 414, 
                    "sentences": [
                        {
                            "text": "Among EGFR ligands, heparin-binding epidermal growth factor (HB-EGF)", 
                            "tokens": [
                                "Among", 
                                "EGFR", 
                                "ligands", 
                                ",", 
                                "heparin-binding", 
                                "epidermal", 
                                "growth", 
                                "factor", 
                                "(", 
                                "HB-EGF", 
                                ")"
                            ]
                        }
                    ], 
                    "text": "Among EGFR ligands, heparin-binding epidermal growth factor (HB-EGF)"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729230", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 357, 
                    "offsetInEndSection": 521, 
                    "sentences": [
                        {
                            "text": " Of the six known EGFR ligands, transforming growth factor alpha (TGF\u03b1) was expressed more highly in triple-negative breast tumors than in tumors of other subtypes.", 
                            "tokens": [
                                "Of", 
                                "the", 
                                "six", 
                                "known", 
                                "EGFR", 
                                "ligands", 
                                ",", 
                                "transforming", 
                                "growth", 
                                "factor", 
                                "alpha", 
                                "(", 
                                "TGF\u03b1", 
                                ")", 
                                "was", 
                                "expressed", 
                                "more", 
                                "highly", 
                                "in", 
                                "triple-negative", 
                                "breast", 
                                "tumors", 
                                "than", 
                                "in", 
                                "tumors", 
                                "of", 
                                "other", 
                                "subtypes", 
                                "."
                            ]
                        }
                    ], 
                    "text": " Of the six known EGFR ligands, transforming growth factor alpha (TGF\u03b1) was expressed more highly in triple-negative breast tumors than in tumors of other subtypes."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23399900", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 781, 
                    "offsetInEndSection": 923, 
                    "sentences": [
                        {
                            "text": "the 7 known EGFR ligands (EGF, betacellulin, epiregulin, heparin-binding EGF, transforming growth factor-\u03b1 [TGF-\u03b1], amphiregulin, and epigen)", 
                            "tokens": [
                                "the", 
                                "7", 
                                "known", 
                                "EGFR", 
                                "ligands", 
                                "(", 
                                "EGF", 
                                ",", 
                                "betacellulin", 
                                ",", 
                                "epiregulin", 
                                ",", 
                                "heparin-binding", 
                                "EGF", 
                                ",", 
                                "transforming", 
                                "growth", 
                                "factor-\u03b1", 
                                "[", 
                                "TGF-\u03b1", 
                                "]", 
                                ",", 
                                "amphiregulin", 
                                ",", 
                                "and", 
                                "epigen", 
                                ")"
                            ]
                        }
                    ], 
                    "text": "the 7 known EGFR ligands (EGF, betacellulin, epiregulin, heparin-binding EGF, transforming growth factor-\u03b1 [TGF-\u03b1], amphiregulin, and epigen) "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23382875", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1393, 
                    "offsetInEndSection": 1472, 
                    "sentences": [
                        {
                            "text": "EGFR ligands based on the two affinity classes: EGF>HB-EGF>TGF-\u03b1>BTC>EPR>EPG>AR", 
                            "tokens": [
                                "EGFR", 
                                "ligands", 
                                "based", 
                                "on", 
                                "the", 
                                "two", 
                                "affinity", 
                                "classes", 
                                ":", 
                                "EGF", 
                                ">", 
                                "HB-EGF", 
                                ">", 
                                "TGF-\u03b1", 
                                ">", 
                                "BTC", 
                                ">", 
                                "EPR", 
                                ">", 
                                "EPG", 
                                ">", 
                                "AR"
                            ]
                        }
                    ], 
                    "text": "EGFR ligands based on the two affinity classes: EGF>HB-EGF>TGF-\u03b1>BTC>EPR>EPG>AR"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23212918", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 197, 
                    "offsetInEndSection": 320, 
                    "sentences": [
                        {
                            "text": "In this article, however, we demonstrate that PEPD directly binds to and activates epidermal growth factor receptor (EGFR),", 
                            "tokens": [
                                "In", 
                                "this", 
                                "article", 
                                ",", 
                                "however", 
                                ",", 
                                "we", 
                                "demonstrate", 
                                "that", 
                                "PEPD", 
                                "directly", 
                                "binds", 
                                "to", 
                                "and", 
                                "activates", 
                                "epidermal", 
                                "growth", 
                                "factor", 
                                "receptor", 
                                "(", 
                                "EGFR", 
                                ")", 
                                ","
                            ]
                        }
                    ], 
                    "text": "In this article, however, we demonstrate that PEPD directly binds to and activates epidermal growth factor receptor (EGFR),"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23099994", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1559, 
                    "offsetInEndSection": 1607, 
                    "sentences": [
                        {
                            "text": "four EGFR ligands (AR, HB-EGF, TGF-\u03b1, and EREG)", 
                            "tokens": [
                                "four", 
                                "EGFR", 
                                "ligands", 
                                "(", 
                                "AR", 
                                ",", 
                                "HB-EGF", 
                                ",", 
                                "TGF-\u03b1", 
                                ",", 
                                "and", 
                                "EREG", 
                                ")"
                            ]
                        }
                    ], 
                    "text": "four EGFR ligands (AR, HB-EGF, TGF-\u03b1, and EREG) "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22260327", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 87, 
                    "sentences": [
                        {
                            "text": "Epidermal growth factor (EGF) family peptides are ligands for the EGF receptor (EGFR).", 
                            "tokens": [
                                "Epidermal", 
                                "growth", 
                                "factor", 
                                "(", 
                                "EGF", 
                                ")", 
                                "family", 
                                "peptides", 
                                "are", 
                                "ligands", 
                                "for", 
                                "the", 
                                "EGF", 
                                "receptor", 
                                "(", 
                                "EGFR", 
                                ")", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Epidermal growth factor (EGF) family peptides are ligands for the EGF receptor (EGFR). "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22260327", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 240, 
                    "offsetInEndSection": 490, 
                    "sentences": [
                        {
                            "text": "oluble amphiregulin (AR), transforming growth factor alpha (TGF\u03b1), neuregulin 2 beta, and epigen stimulate greater EGFR coupling to cell proliferation and DNA synthesis than do EGF, betacellulin, heparin-binding EGF-like growth factor, and epiregulin", 
                            "tokens": [
                                "oluble", 
                                "amphiregulin", 
                                "(", 
                                "AR", 
                                ")", 
                                ",", 
                                "transforming", 
                                "growth", 
                                "factor", 
                                "alpha", 
                                "(", 
                                "TGF\u03b1", 
                                ")", 
                                ",", 
                                "neuregulin", 
                                "2", 
                                "beta", 
                                ",", 
                                "and", 
                                "epigen", 
                                "stimulate", 
                                "greater", 
                                "EGFR", 
                                "coupling", 
                                "to", 
                                "cell", 
                                "proliferation", 
                                "and", 
                                "DNA", 
                                "synthesis", 
                                "than", 
                                "do", 
                                "EGF", 
                                ",", 
                                "betacellulin", 
                                ",", 
                                "heparin-binding", 
                                "EGF-like", 
                                "growth", 
                                "factor", 
                                ",", 
                                "and", 
                                "epiregulin"
                            ]
                        }
                    ], 
                    "text": "oluble amphiregulin (AR), transforming growth factor alpha (TGF\u03b1), neuregulin 2 beta, and epigen stimulate greater EGFR coupling to cell proliferation and DNA synthesis than do EGF, betacellulin, heparin-binding EGF-like growth factor, and epiregulin"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22247333", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 387, 
                    "offsetInEndSection": 563, 
                    "sentences": [
                        {
                            "text": "Here, we demonstrate that histamine releases 2 EGFR ligands, amphiregulin and heparin-binding epidermal growth factor-like growth factor (HB-EGF), from airway epithelial cells.", 
                            "tokens": [
                                "Here", 
                                ",", 
                                "we", 
                                "demonstrate", 
                                "that", 
                                "histamine", 
                                "releases", 
                                "2", 
                                "EGFR", 
                                "ligands", 
                                ",", 
                                "amphiregulin", 
                                "and", 
                                "heparin-binding", 
                                "epidermal", 
                                "growth", 
                                "factor-like", 
                                "growth", 
                                "factor", 
                                "(", 
                                "HB-EGF", 
                                ")", 
                                ",", 
                                "from", 
                                "airway", 
                                "epithelial", 
                                "cells", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Here, we demonstrate that histamine releases 2 EGFR ligands, amphiregulin and heparin-binding epidermal growth factor-like growth factor (HB-EGF), from airway epithelial cells."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21514161", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 72, 
                    "offsetInEndSection": 231, 
                    "sentences": [
                        {
                            "text": "mammalian EGFR ligands including EGF, TGF-\u03b1 (TGF\u03b1), amphiregulin (AREG), heparin-binding EGF-like growth factor (HB-EGF), betacellulin, epiregulin, and epigen.", 
                            "tokens": [
                                "mammalian", 
                                "EGFR", 
                                "ligands", 
                                "including", 
                                "EGF", 
                                ",", 
                                "TGF-\u03b1", 
                                "(", 
                                "TGF\u03b1", 
                                ")", 
                                ",", 
                                "amphiregulin", 
                                "(", 
                                "AREG", 
                                ")", 
                                ",", 
                                "heparin-binding", 
                                "EGF-like", 
                                "growth", 
                                "factor", 
                                "(", 
                                "HB-EGF", 
                                ")", 
                                ",", 
                                "betacellulin", 
                                ",", 
                                "epiregulin", 
                                ",", 
                                "and", 
                                "epigen", 
                                "."
                            ]
                        }
                    ], 
                    "text": "mammalian EGFR ligands including EGF, TGF-\u03b1 (TGF\u03b1), amphiregulin (AREG), heparin-binding EGF-like growth factor (HB-EGF), betacellulin, epiregulin, and epigen."
                }
            ], 
            "tokens": [
                "List", 
                "signaling", 
                "molecules", 
                "(", 
                "ligands", 
                ")", 
                "that", 
                "interact", 
                "with", 
                "the", 
                "receptor", 
                "EGFR", 
                "?"
            ], 
            "triples": [
                {
                    "o": "http://linkedlifedata.com/resource/#_5139515837300022", 
                    "p": "http://purl.uniprot.org/core/encodedBy", 
                    "s": "http://purl.uniprot.org/uniprot/Q9QX70"
                }, 
                {
                    "o": "Egfr", 
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel", 
                    "s": "http://linkedlifedata.com/resource/#_5139515837300022"
                }, 
                {
                    "o": "http://purl.uniprot.org/uniprot/Q9QX70", 
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                    "s": "http://purl.uniprot.org/intact/EBI-1256812"
                }, 
                {
                    "o": "Egfr", 
                    "p": "http://www.w3.org/2000/01/rdf-schema#label", 
                    "s": "http://purl.uniprot.org/intact/EBI-1256812"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Is the protein Papilin secreted?", 
            "concepts": [], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21784067", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20805556", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19724244", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19297413", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15094122", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15094110", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12666201", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11076767", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7515725", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3320045"
            ], 
            "exact_answer": "Papilin is an extracellular matrix glycoproteinapilins are homologous, secreted extracellular matrix proteins which share a common order of protein domains.Both MIG-6 isoforms have a predicted N-terminal papilin cassetteThis review samples some of the contemporary literature regarding TSR superfamily members (e.g.F-spondin, UNC-5, ADAMTS, papilin, and TRAP) where specific functions are assigned to the TSR domains.A sulfated glycoprotein was isolated from the culture media of Drosophila Kc cells and named papilin.We found that mig-6 encodes long (MIG-6L) and short (MIG-6S) isoforms of the extracellular matrix protein papilin, each required for distinct aspects of DTC migration. Collagen IV, laminin, glutactin, papilin, and other extracellular matrix proteins were made primarily by hemocytes and were secreted into the medium.Using expression analysis, we identify three genes that are transcriptionally regulated by HLH-2: the protocadherin cdh-3, and two genes encoding secreted extracellular matrix proteins, mig-6/papilin and him-4/hemicentin.", 
            "id": "54e25eaaae9738404b000017", 
            "ideal_answer": [
                "Yes,  papilin is a secreted protein"
            ], 
            "ranked": [
                "Papilin is an extracellular matrix glycoprotein", 
                "apilins are homologous, secreted extracellular matrix proteins which share a common order of protein domains.", 
                "Both MIG-6 isoforms have a predicted N-terminal papilin cassette", 
                "This review samples some of the contemporary literature regarding TSR superfamily members (e.g.", 
                "F-spondin, UNC-5, ADAMTS, papilin, and TRAP) where specific functions are assigned to the TSR domains.", 
                "A sulfated glycoprotein was isolated from the culture media of Drosophila Kc cells and named papilin.", 
                "We found that mig-6 encodes long (MIG-6L) and short (MIG-6S) isoforms of the extracellular matrix protein papilin, each required for distinct aspects of DTC migration.", 
                " Collagen IV, laminin, glutactin, papilin, and other extracellular matrix proteins were made primarily by hemocytes and were secreted into the medium.", 
                "Using expression analysis, we identify three genes that are transcriptionally regulated by HLH-2: the protocadherin cdh-3, and two genes encoding secreted extracellular matrix proteins, mig-6/papilin and him-4/hemicentin.", 
                "The TSR superfamily is a diverse family of extracellular matrix and transmembrane proteins, many of which have functions related to regulating matrix organization, cell-cell interactions and cell guidance."
            ], 
            "snippets": [
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21784067", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1085, 
                    "offsetInEndSection": 1307, 
                    "sentences": [
                        {
                            "text": "Using expression analysis, we identify three genes that are transcriptionally regulated by HLH-2: the protocadherin cdh-3, and two genes encoding secreted extracellular matrix proteins, mig-6/papilin and him-4/hemicentin.", 
                            "tokens": [
                                "Using", 
                                "expression", 
                                "analysis", 
                                ",", 
                                "we", 
                                "identify", 
                                "three", 
                                "genes", 
                                "that", 
                                "are", 
                                "transcriptionally", 
                                "regulated", 
                                "by", 
                                "HLH-2", 
                                ":", 
                                "the", 
                                "protocadherin", 
                                "cdh-3", 
                                ",", 
                                "and", 
                                "two", 
                                "genes", 
                                "encoding", 
                                "secreted", 
                                "extracellular", 
                                "matrix", 
                                "proteins", 
                                ",", 
                                "mig-6/papilin", 
                                "and", 
                                "him-4/hemicentin", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Using expression analysis, we identify three genes that are transcriptionally regulated by HLH-2: the protocadherin cdh-3, and two genes encoding secreted extracellular matrix proteins, mig-6/papilin and him-4/hemicentin. "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19297413", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 226, 
                    "offsetInEndSection": 458, 
                    "sentences": [
                        {
                            "text": "We found that mig-6 encodes long (MIG-6L) and short (MIG-6S) isoforms of the extracellular matrix protein papilin, each required for distinct aspects of DTC migration.", 
                            "tokens": [
                                "We", 
                                "found", 
                                "that", 
                                "mig-6", 
                                "encodes", 
                                "long", 
                                "(", 
                                "MIG-6L", 
                                ")", 
                                "and", 
                                "short", 
                                "(", 
                                "MIG-6S", 
                                ")", 
                                "isoforms", 
                                "of", 
                                "the", 
                                "extracellular", 
                                "matrix", 
                                "protein", 
                                "papilin", 
                                ",", 
                                "each", 
                                "required", 
                                "for", 
                                "distinct", 
                                "aspects", 
                                "of", 
                                "DTC", 
                                "migration", 
                                "."
                            ]
                        }, 
                        {
                            "text": "Both MIG-6 isoforms have a predicted N-terminal papilin cassette", 
                            "tokens": [
                                "Both", 
                                "MIG-6", 
                                "isoforms", 
                                "have", 
                                "a", 
                                "predicted", 
                                "N-terminal", 
                                "papilin", 
                                "cassette"
                            ]
                        }
                    ], 
                    "text": "We found that mig-6 encodes long (MIG-6L) and short (MIG-6S) isoforms of the extracellular matrix protein papilin, each required for distinct aspects of DTC migration. Both MIG-6 isoforms have a predicted N-terminal papilin cassette"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15094122", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1, 
                    "offsetInEndSection": 111, 
                    "sentences": [
                        {
                            "text": "apilins are homologous, secreted extracellular matrix proteins which share a common order of protein domains.", 
                            "tokens": [
                                "apilins", 
                                "are", 
                                "homologous", 
                                ",", 
                                "secreted", 
                                "extracellular", 
                                "matrix", 
                                "proteins", 
                                "which", 
                                "share", 
                                "a", 
                                "common", 
                                "order", 
                                "of", 
                                "protein", 
                                "domains", 
                                "."
                            ]
                        }
                    ], 
                    "text": "apilins are homologous, secreted extracellular matrix proteins which share a common order of protein domains. "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15094110", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 404, 
                    "sentences": [
                        {
                            "text": "The TSR superfamily is a diverse family of extracellular matrix and transmembrane proteins, many of which have functions related to regulating matrix organization, cell-cell interactions and cell guidance.", 
                            "tokens": [
                                "The", 
                                "TSR", 
                                "superfamily", 
                                "is", 
                                "a", 
                                "diverse", 
                                "family", 
                                "of", 
                                "extracellular", 
                                "matrix", 
                                "and", 
                                "transmembrane", 
                                "proteins", 
                                ",", 
                                "many", 
                                "of", 
                                "which", 
                                "have", 
                                "functions", 
                                "related", 
                                "to", 
                                "regulating", 
                                "matrix", 
                                "organization", 
                                ",", 
                                "cell-cell", 
                                "interactions", 
                                "and", 
                                "cell", 
                                "guidance", 
                                "."
                            ]
                        }, 
                        {
                            "text": "This review samples some of the contemporary literature regarding TSR superfamily members (e.g.", 
                            "tokens": [
                                "This", 
                                "review", 
                                "samples", 
                                "some", 
                                "of", 
                                "the", 
                                "contemporary", 
                                "literature", 
                                "regarding", 
                                "TSR", 
                                "superfamily", 
                                "members", 
                                "(", 
                                "e.g", 
                                "."
                            ]
                        }, 
                        {
                            "text": "F-spondin, UNC-5, ADAMTS, papilin, and TRAP) where specific functions are assigned to the TSR domains.", 
                            "tokens": [
                                "F-spondin", 
                                ",", 
                                "UNC-5", 
                                ",", 
                                "ADAMTS", 
                                ",", 
                                "papilin", 
                                ",", 
                                "and", 
                                "TRAP", 
                                ")", 
                                "where", 
                                "specific", 
                                "functions", 
                                "are", 
                                "assigned", 
                                "to", 
                                "the", 
                                "TSR", 
                                "domains", 
                                "."
                            ]
                        }
                    ], 
                    "text": "The TSR superfamily is a diverse family of extracellular matrix and transmembrane proteins, many of which have functions related to regulating matrix organization, cell-cell interactions and cell guidance. This review samples some of the contemporary literature regarding TSR superfamily members (e.g. F-spondin, UNC-5, ADAMTS, papilin, and TRAP) where specific functions are assigned to the TSR domains."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12666201", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 43, 
                    "sentences": [
                        {
                            "text": "Papilins are extracellular matrix proteins", 
                            "tokens": [
                                "Papilins", 
                                "are", 
                                "extracellular", 
                                "matrix", 
                                "proteins"
                            ]
                        }
                    ], 
                    "text": "Papilins are extracellular matrix proteins "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11076767", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 48, 
                    "sentences": [
                        {
                            "text": "Papilin is an extracellular matrix glycoprotein", 
                            "tokens": [
                                "Papilin", 
                                "is", 
                                "an", 
                                "extracellular", 
                                "matrix", 
                                "glycoprotein"
                            ]
                        }
                    ], 
                    "text": "Papilin is an extracellular matrix glycoprotein "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7515725", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 731, 
                    "offsetInEndSection": 882, 
                    "sentences": [
                        {
                            "text": " Collagen IV, laminin, glutactin, papilin, and other extracellular matrix proteins were made primarily by hemocytes and were secreted into the medium.", 
                            "tokens": [
                                "Collagen", 
                                "IV", 
                                ",", 
                                "laminin", 
                                ",", 
                                "glutactin", 
                                ",", 
                                "papilin", 
                                ",", 
                                "and", 
                                "other", 
                                "extracellular", 
                                "matrix", 
                                "proteins", 
                                "were", 
                                "made", 
                                "primarily", 
                                "by", 
                                "hemocytes", 
                                "and", 
                                "were", 
                                "secreted", 
                                "into", 
                                "the", 
                                "medium", 
                                "."
                            ]
                        }
                    ], 
                    "text": " Collagen IV, laminin, glutactin, papilin, and other extracellular matrix proteins were made primarily by hemocytes and were secreted into the medium. "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3320045", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 101, 
                    "sentences": [
                        {
                            "text": "A sulfated glycoprotein was isolated from the culture media of Drosophila Kc cells and named papilin.", 
                            "tokens": [
                                "A", 
                                "sulfated", 
                                "glycoprotein", 
                                "was", 
                                "isolated", 
                                "from", 
                                "the", 
                                "culture", 
                                "media", 
                                "of", 
                                "Drosophila", 
                                "Kc", 
                                "cells", 
                                "and", 
                                "named", 
                                "papilin", 
                                "."
                            ]
                        }
                    ], 
                    "text": "A sulfated glycoprotein was isolated from the culture media of Drosophila Kc cells and named papilin."
                }
            ], 
            "tokens": [
                "Is", 
                "the", 
                "protein", 
                "Papilin", 
                "secreted", 
                "?"
            ], 
            "triples": [], 
            "type": "yesno"
        }, 
        {
            "body": "Are long non coding RNAs spliced?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D062085", 
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012326"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22955988", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22955974", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22707570", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21622663", 
                "http://www.ncbi.nlm.nih.gov/pubmed/24285305", 
                "http://www.ncbi.nlm.nih.gov/pubmed/24106460"
            ], 
            "exact_answer": "For alternative exons and long noncoding RNAs, splicing tends to occur later, and the latter might remain unspliced in some cases.We introduce an approach to predict spliced lncRNAs in vertebrate genomes combining comparative genomics and machine learning.We found 170 long intervening ncRNAs (lincRNAs), which had single- or multiexonic structures that did not overlap protein-coding transcripts, and about sixty antisense lncRNAs (ancRNAs), which were complementary to protein-coding transcriptsOur synthesis of recent studies suggests that neither size, presence of a poly-A tail, splicing, direction of transcription, nor strand specificity are of importance to lncRNA function.Our analyses indicate that lncRNAs are generated through pathways similar to that of protein-coding genes, with similar histone-modification profiles, splicing signals, and exon/intron lengths.bosome-mapping data to identify lncRNAs of Caenorhabditis elegans.Owing to similar alternative splicing pattern to mRNAs, the concept of lncRNA genes was put forward to help systematic understanding of lncRNAs.For alternative exons and long noncoding RNAs, splicing tends to occur later, and the latter might remain unspliced in some cases.", 
            "id": "535d292a9a4572de6f000003", 
            "ideal_answer": [
                "Long non coding RNAs appear to be spliced through the same pathway as the mRNAs"
            ], 
            "ranked": [
                "For alternative exons and long noncoding RNAs, splicing tends to occur later, and the latter might remain unspliced in some cases.", 
                "We introduce an approach to predict spliced lncRNAs in vertebrate genomes combining comparative genomics and machine learning.", 
                "We found 170 long intervening ncRNAs (lincRNAs), which had single- or multiexonic structures that did not overlap protein-coding transcripts, and about sixty antisense lncRNAs (ancRNAs), which were complementary to protein-coding transcripts", 
                "Our synthesis of recent studies suggests that neither size, presence of a poly-A tail, splicing, direction of transcription, nor strand specificity are of importance to lncRNA function.", 
                "Our analyses indicate that lncRNAs are generated through pathways similar to that of protein-coding genes, with similar histone-modification profiles, splicing signals, and exon/intron lengths.", 
                "bosome-mapping data to identify lncRNAs of Caenorhabditis elegans.", 
                "Owing to similar alternative splicing pattern to mRNAs, the concept of lncRNA genes was put forward to help systematic understanding of lncRNAs.", 
                "For alternative exons and long noncoding RNAs, splicing tends to occur later, and the latter might remain unspliced in some cases.", 
                "Our analyses indicate that lncRNAs are generated through pathways similar to that of protein-coding genes, with similar histone-modification profiles, splicing signals, and exon/intron lengths.", 
                "Our analyses indicate that lncRNAs are generated through pathways similar to that of protein-coding genes, with similar histone-modification profiles, splicing signals, and exon/intron lengths."
            ], 
            "snippets": [
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955988", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 546, 
                    "offsetInEndSection": 739, 
                    "sentences": [
                        {
                            "text": "Our analyses indicate that lncRNAs are generated through pathways similar to that of protein-coding genes, with similar histone-modification profiles, splicing signals, and exon/intron lengths.", 
                            "tokens": [
                                "Our", 
                                "analyses", 
                                "indicate", 
                                "that", 
                                "lncRNAs", 
                                "are", 
                                "generated", 
                                "through", 
                                "pathways", 
                                "similar", 
                                "to", 
                                "that", 
                                "of", 
                                "protein-coding", 
                                "genes", 
                                ",", 
                                "with", 
                                "similar", 
                                "histone-modification", 
                                "profiles", 
                                ",", 
                                "splicing", 
                                "signals", 
                                ",", 
                                "and", 
                                "exon/intron", 
                                "lengths", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Our analyses indicate that lncRNAs are generated through pathways similar to that of protein-coding genes, with similar histone-modification profiles, splicing signals, and exon/intron lengths."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955974", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1602, 
                    "offsetInEndSection": 1732, 
                    "sentences": [
                        {
                            "text": "For alternative exons and long noncoding RNAs, splicing tends to occur later, and the latter might remain unspliced in some cases.", 
                            "tokens": [
                                "For", 
                                "alternative", 
                                "exons", 
                                "and", 
                                "long", 
                                "noncoding", 
                                "RNAs", 
                                ",", 
                                "splicing", 
                                "tends", 
                                "to", 
                                "occur", 
                                "later", 
                                ",", 
                                "and", 
                                "the", 
                                "latter", 
                                "might", 
                                "remain", 
                                "unspliced", 
                                "in", 
                                "some", 
                                "cases", 
                                "."
                            ]
                        }
                    ], 
                    "text": "For alternative exons and long noncoding RNAs, splicing tends to occur later, and the latter might remain unspliced in some cases."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22707570", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 249, 
                    "offsetInEndSection": 557, 
                    "sentences": [
                        {
                            "text": "bosome-mapping data to identify lncRNAs of Caenorhabditis elegans.", 
                            "tokens": [
                                "bosome-mapping", 
                                "data", 
                                "to", 
                                "identify", 
                                "lncRNAs", 
                                "of", 
                                "Caenorhabditis", 
                                "elegans", 
                                "."
                            ]
                        }, 
                        {
                            "text": "We found 170 long intervening ncRNAs (lincRNAs), which had single- or multiexonic structures that did not overlap protein-coding transcripts, and about sixty antisense lncRNAs (ancRNAs), which were complementary to protein-coding transcripts", 
                            "tokens": [
                                "We", 
                                "found", 
                                "170", 
                                "long", 
                                "intervening", 
                                "ncRNAs", 
                                "(", 
                                "lincRNAs", 
                                ")", 
                                ",", 
                                "which", 
                                "had", 
                                "single-", 
                                "or", 
                                "multiexonic", 
                                "structures", 
                                "that", 
                                "did", 
                                "not", 
                                "overlap", 
                                "protein-coding", 
                                "transcripts", 
                                ",", 
                                "and", 
                                "about", 
                                "sixty", 
                                "antisense", 
                                "lncRNAs", 
                                "(", 
                                "ancRNAs", 
                                ")", 
                                ",", 
                                "which", 
                                "were", 
                                "complementary", 
                                "to", 
                                "protein-coding", 
                                "transcripts"
                            ]
                        }
                    ], 
                    "text": "bosome-mapping data to identify lncRNAs of Caenorhabditis elegans. We found 170 long intervening ncRNAs (lincRNAs), which had single- or multiexonic structures that did not overlap protein-coding transcripts, and about sixty antisense lncRNAs (ancRNAs), which were complementary to protein-coding transcripts"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21622663", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 275, 
                    "offsetInEndSection": 401, 
                    "sentences": [
                        {
                            "text": "We introduce an approach to predict spliced lncRNAs in vertebrate genomes combining comparative genomics and machine learning.", 
                            "tokens": [
                                "We", 
                                "introduce", 
                                "an", 
                                "approach", 
                                "to", 
                                "predict", 
                                "spliced", 
                                "lncRNAs", 
                                "in", 
                                "vertebrate", 
                                "genomes", 
                                "combining", 
                                "comparative", 
                                "genomics", 
                                "and", 
                                "machine", 
                                "learning", 
                                "."
                            ]
                        }
                    ], 
                    "text": "We introduce an approach to predict spliced lncRNAs in vertebrate genomes combining comparative genomics and machine learning."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285305", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 711, 
                    "offsetInEndSection": 856, 
                    "sentences": [
                        {
                            "text": "Owing to similar alternative splicing pattern to mRNAs, the concept of lncRNA genes was put forward to help systematic understanding of lncRNAs.", 
                            "tokens": [
                                "Owing", 
                                "to", 
                                "similar", 
                                "alternative", 
                                "splicing", 
                                "pattern", 
                                "to", 
                                "mRNAs", 
                                ",", 
                                "the", 
                                "concept", 
                                "of", 
                                "lncRNA", 
                                "genes", 
                                "was", 
                                "put", 
                                "forward", 
                                "to", 
                                "help", 
                                "systematic", 
                                "understanding", 
                                "of", 
                                "lncRNAs", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Owing to similar alternative splicing pattern to mRNAs, the concept of lncRNA genes was put forward to help systematic understanding of lncRNAs. "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24106460", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 561, 
                    "offsetInEndSection": 746, 
                    "sentences": [
                        {
                            "text": "Our synthesis of recent studies suggests that neither size, presence of a poly-A tail, splicing, direction of transcription, nor strand specificity are of importance to lncRNA function.", 
                            "tokens": [
                                "Our", 
                                "synthesis", 
                                "of", 
                                "recent", 
                                "studies", 
                                "suggests", 
                                "that", 
                                "neither", 
                                "size", 
                                ",", 
                                "presence", 
                                "of", 
                                "a", 
                                "poly-A", 
                                "tail", 
                                ",", 
                                "splicing", 
                                ",", 
                                "direction", 
                                "of", 
                                "transcription", 
                                ",", 
                                "nor", 
                                "strand", 
                                "specificity", 
                                "are", 
                                "of", 
                                "importance", 
                                "to", 
                                "lncRNA", 
                                "function", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Our synthesis of recent studies suggests that neither size, presence of a poly-A tail, splicing, direction of transcription, nor strand specificity are of importance to lncRNA function."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955988", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 546, 
                    "offsetInEndSection": 739, 
                    "sentences": [
                        {
                            "text": "Our analyses indicate that lncRNAs are generated through pathways similar to that of protein-coding genes, with similar histone-modification profiles, splicing signals, and exon/intron lengths.", 
                            "tokens": [
                                "Our", 
                                "analyses", 
                                "indicate", 
                                "that", 
                                "lncRNAs", 
                                "are", 
                                "generated", 
                                "through", 
                                "pathways", 
                                "similar", 
                                "to", 
                                "that", 
                                "of", 
                                "protein-coding", 
                                "genes", 
                                ",", 
                                "with", 
                                "similar", 
                                "histone-modification", 
                                "profiles", 
                                ",", 
                                "splicing", 
                                "signals", 
                                ",", 
                                "and", 
                                "exon/intron", 
                                "lengths", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Our analyses indicate that lncRNAs are generated through pathways similar to that of protein-coding genes, with similar histone-modification profiles, splicing signals, and exon/intron lengths."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955974", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1602, 
                    "offsetInEndSection": 1732, 
                    "sentences": [
                        {
                            "text": "For alternative exons and long noncoding RNAs, splicing tends to occur later, and the latter might remain unspliced in some cases.", 
                            "tokens": [
                                "For", 
                                "alternative", 
                                "exons", 
                                "and", 
                                "long", 
                                "noncoding", 
                                "RNAs", 
                                ",", 
                                "splicing", 
                                "tends", 
                                "to", 
                                "occur", 
                                "later", 
                                ",", 
                                "and", 
                                "the", 
                                "latter", 
                                "might", 
                                "remain", 
                                "unspliced", 
                                "in", 
                                "some", 
                                "cases", 
                                "."
                            ]
                        }
                    ], 
                    "text": "For alternative exons and long noncoding RNAs, splicing tends to occur later, and the latter might remain unspliced in some cases."
                }
            ], 
            "tokens": [
                "Are", 
                "long", 
                "non", 
                "coding", 
                "RNAs", 
                "spliced", 
                "?"
            ], 
            "triples": [], 
            "type": "yesno"
        }, 
        {
            "body": "Is RANKL secreted from the cells?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015870", 
                "http://www.uniprot.org/uniprot/TNF11_RAT", 
                "http://www.uniprot.org/uniprot/TNF11_HUMAN"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24267510", 
                "http://www.ncbi.nlm.nih.gov/pubmed/24265865", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23835909", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23827649", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23698708", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23632157", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22948539", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22901753", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22867712", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21618594"
            ], 
            "exact_answer": "Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL.OPG, on the other hand, is secreted by osteoblast as a decoy receptor for RANKL, prevents RANKL from binding to RANK and thus prevents bone resorptionAlthough B. abortus-activated T cells actively secreted the pro-osteoclastogenic cytokines RANKL and IL-17, osteoclastogenesis depended on IL-17, because osteoclast generation induced by Brucella-activated T cells was completely abrogated when these cells were cultured with BMMs from IL-17 receptor knockout mice.Receptor activator of nuclear factor \u03baB ligand (RANKL) and osteoprotegerin (OPG) are cytokines predominantly secreted by osteoblasts and play a central role in differentiation and functional activation of osteoclastsWe isolated human fibroblasts from RA, pyrophosphate arthropathy (PPA) and osteoarthritis (OA) patients and analyzed their RANKL/OPG expression profile and the capacity of their secreted factors to induce osteoclastogenesis.We identify a TNFSF11 transcript variant that extends the originally identified transcript encoding secreted RANKL. osteoclastogenesis and bone destruction in autoimmune arthritis.e RANKL/OPG ratio secreted by osteoblasts increased and RANK expression by osteoclasts increased, leading to increased osteoclastogenesis", 
            "id": "55262a9787ecba3764000009", 
            "ideal_answer": [
                "Receptor activator of nuclear factor \u03baB ligand (RANKL) is a cytokine predominantly secreted by osteoblasts."
            ], 
            "ranked": [
                "Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL.", 
                "OPG, on the other hand, is secreted by osteoblast as a decoy receptor for RANKL, prevents RANKL from binding to RANK and thus prevents bone resorption", 
                "Although B. abortus-activated T cells actively secreted the pro-osteoclastogenic cytokines RANKL and IL-17, osteoclastogenesis depended on IL-17, because osteoclast generation induced by Brucella-activated T cells was completely abrogated when these cells were cultured with BMMs from IL-17 receptor knockout mice.", 
                "Receptor activator of nuclear factor \u03baB ligand (RANKL) and osteoprotegerin (OPG) are cytokines predominantly secreted by osteoblasts and play a central role in differentiation and functional activation of osteoclasts", 
                "We isolated human fibroblasts from RA, pyrophosphate arthropathy (PPA) and osteoarthritis (OA) patients and analyzed their RANKL/OPG expression profile and the capacity of their secreted factors to induce osteoclastogenesis.", 
                "We identify a TNFSF11 transcript variant that extends the originally identified transcript encoding secreted RANKL.", 
                " osteoclastogenesis and bone destruction in autoimmune arthritis.", 
                "e RANKL/OPG ratio secreted by osteoblasts increased and RANK expression by osteoclasts increased, leading to increased osteoclastogenesis", 
                "Osteoprotegerin (OPG) is a secreted glycoprotein and a member of the tumor necrosis factor receptor superfamily.", 
                "It usually functions in bone remodeling, by inhibiting osteoclastogenesis through interaction with a receptor activator of the nuclear factor \u03baB (RANKL)."
            ], 
            "snippets": [
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24267510", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 114, 
                    "offsetInEndSection": 242, 
                    "sentences": [
                        {
                            "text": "Osteoprotegerin (OPG) is a soluble secreted factor that acts as a decoy receptor for receptor activator of NF-\u03baB ligand (RANKL)", 
                            "tokens": [
                                "Osteoprotegerin", 
                                "(", 
                                "OPG", 
                                ")", 
                                "is", 
                                "a", 
                                "soluble", 
                                "secreted", 
                                "factor", 
                                "that", 
                                "acts", 
                                "as", 
                                "a", 
                                "decoy", 
                                "receptor", 
                                "for", 
                                "receptor", 
                                "activator", 
                                "of", 
                                "NF-\u03baB", 
                                "ligand", 
                                "(", 
                                "RANKL", 
                                ")"
                            ]
                        }
                    ], 
                    "text": "Osteoprotegerin (OPG) is a soluble secreted factor that acts as a decoy receptor for receptor activator of NF-\u03baB ligand (RANKL) "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265865", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 266, 
                    "sentences": [
                        {
                            "text": "Osteoprotegerin (OPG) is a secreted glycoprotein and a member of the tumor necrosis factor receptor superfamily.", 
                            "tokens": [
                                "Osteoprotegerin", 
                                "(", 
                                "OPG", 
                                ")", 
                                "is", 
                                "a", 
                                "secreted", 
                                "glycoprotein", 
                                "and", 
                                "a", 
                                "member", 
                                "of", 
                                "the", 
                                "tumor", 
                                "necrosis", 
                                "factor", 
                                "receptor", 
                                "superfamily", 
                                "."
                            ]
                        }, 
                        {
                            "text": "It usually functions in bone remodeling, by inhibiting osteoclastogenesis through interaction with a receptor activator of the nuclear factor \u03baB (RANKL).", 
                            "tokens": [
                                "It", 
                                "usually", 
                                "functions", 
                                "in", 
                                "bone", 
                                "remodeling", 
                                ",", 
                                "by", 
                                "inhibiting", 
                                "osteoclastogenesis", 
                                "through", 
                                "interaction", 
                                "with", 
                                "a", 
                                "receptor", 
                                "activator", 
                                "of", 
                                "the", 
                                "nuclear", 
                                "factor", 
                                "\u03baB", 
                                "(", 
                                "RANKL", 
                                ")", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Osteoprotegerin (OPG) is a secreted glycoprotein and a member of the tumor necrosis factor receptor superfamily. It usually functions in bone remodeling, by inhibiting osteoclastogenesis through interaction with a receptor activator of the nuclear factor \u03baB (RANKL)."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23835909", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1110, 
                    "offsetInEndSection": 1247, 
                    "sentences": [
                        {
                            "text": "e RANKL/OPG ratio secreted by osteoblasts increased and RANK expression by osteoclasts increased, leading to increased osteoclastogenesis", 
                            "tokens": [
                                "e", 
                                "RANKL/OPG", 
                                "ratio", 
                                "secreted", 
                                "by", 
                                "osteoblasts", 
                                "increased", 
                                "and", 
                                "RANK", 
                                "expression", 
                                "by", 
                                "osteoclasts", 
                                "increased", 
                                ",", 
                                "leading", 
                                "to", 
                                "increased", 
                                "osteoclastogenesis"
                            ]
                        }
                    ], 
                    "text": "e RANKL/OPG ratio secreted by osteoblasts increased and RANK expression by osteoclasts increased, leading to increased osteoclastogenesis"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23827649", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 228, 
                    "sentences": [
                        {
                            "text": "Osteoprotegerin (OPG) is an essential secreted protein in bone turnover due to its role as a decoy receptor for the Receptor Activator of Nuclear Factor-kB ligand (RANKL) in the osteoclasts, thus inhibiting their differentiation", 
                            "tokens": [
                                "Osteoprotegerin", 
                                "(", 
                                "OPG", 
                                ")", 
                                "is", 
                                "an", 
                                "essential", 
                                "secreted", 
                                "protein", 
                                "in", 
                                "bone", 
                                "turnover", 
                                "due", 
                                "to", 
                                "its", 
                                "role", 
                                "as", 
                                "a", 
                                "decoy", 
                                "receptor", 
                                "for", 
                                "the", 
                                "Receptor", 
                                "Activator", 
                                "of", 
                                "Nuclear", 
                                "Factor-kB", 
                                "ligand", 
                                "(", 
                                "RANKL", 
                                ")", 
                                "in", 
                                "the", 
                                "osteoclasts", 
                                ",", 
                                "thus", 
                                "inhibiting", 
                                "their", 
                                "differentiation"
                            ]
                        }
                    ], 
                    "text": "Osteoprotegerin (OPG) is an essential secreted protein in bone turnover due to its role as a decoy receptor for the Receptor Activator of Nuclear Factor-kB ligand (RANKL) in the osteoclasts, thus inhibiting their differentiation"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23698708", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 324, 
                    "offsetInEndSection": 439, 
                    "sentences": [
                        {
                            "text": "We identify a TNFSF11 transcript variant that extends the originally identified transcript encoding secreted RANKL.", 
                            "tokens": [
                                "We", 
                                "identify", 
                                "a", 
                                "TNFSF11", 
                                "transcript", 
                                "variant", 
                                "that", 
                                "extends", 
                                "the", 
                                "originally", 
                                "identified", 
                                "transcript", 
                                "encoding", 
                                "secreted", 
                                "RANKL", 
                                "."
                            ]
                        }
                    ], 
                    "text": "We identify a TNFSF11 transcript variant that extends the originally identified transcript encoding secreted RANKL."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23698708", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 95, 
                    "sentences": [
                        {
                            "text": "Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL.", 
                            "tokens": [
                                "Activated", 
                                "human", 
                                "T", 
                                "cells", 
                                "express", 
                                "alternative", 
                                "mRNA", 
                                "transcripts", 
                                "encoding", 
                                "a", 
                                "secreted", 
                                "form", 
                                "of", 
                                "RANKL", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23632157", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 471, 
                    "offsetInEndSection": 621, 
                    "sentences": [
                        {
                            "text": "OPG, on the other hand, is secreted by osteoblast as a decoy receptor for RANKL, prevents RANKL from binding to RANK and thus prevents bone resorption", 
                            "tokens": [
                                "OPG", 
                                ",", 
                                "on", 
                                "the", 
                                "other", 
                                "hand", 
                                ",", 
                                "is", 
                                "secreted", 
                                "by", 
                                "osteoblast", 
                                "as", 
                                "a", 
                                "decoy", 
                                "receptor", 
                                "for", 
                                "RANKL", 
                                ",", 
                                "prevents", 
                                "RANKL", 
                                "from", 
                                "binding", 
                                "to", 
                                "RANK", 
                                "and", 
                                "thus", 
                                "prevents", 
                                "bone", 
                                "resorption"
                            ]
                        }
                    ], 
                    "text": "OPG, on the other hand, is secreted by osteoblast as a decoy receptor for RANKL, prevents RANKL from binding to RANK and thus prevents bone resorption"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22948539", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 270, 
                    "offsetInEndSection": 486, 
                    "sentences": [
                        {
                            "text": "Receptor activator of nuclear factor \u03baB ligand (RANKL) and osteoprotegerin (OPG) are cytokines predominantly secreted by osteoblasts and play a central role in differentiation and functional activation of osteoclasts", 
                            "tokens": [
                                "Receptor", 
                                "activator", 
                                "of", 
                                "nuclear", 
                                "factor", 
                                "\u03baB", 
                                "ligand", 
                                "(", 
                                "RANKL", 
                                ")", 
                                "and", 
                                "osteoprotegerin", 
                                "(", 
                                "OPG", 
                                ")", 
                                "are", 
                                "cytokines", 
                                "predominantly", 
                                "secreted", 
                                "by", 
                                "osteoblasts", 
                                "and", 
                                "play", 
                                "a", 
                                "central", 
                                "role", 
                                "in", 
                                "differentiation", 
                                "and", 
                                "functional", 
                                "activation", 
                                "of", 
                                "osteoclasts"
                            ]
                        }
                    ], 
                    "text": "Receptor activator of nuclear factor \u03baB ligand (RANKL) and osteoprotegerin (OPG) are cytokines predominantly secreted by osteoblasts and play a central role in differentiation and functional activation of osteoclasts"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22901753", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 690, 
                    "offsetInEndSection": 1005, 
                    "sentences": [
                        {
                            "text": "Although B. abortus-activated T cells actively secreted the pro-osteoclastogenic cytokines RANKL and IL-17, osteoclastogenesis depended on IL-17, because osteoclast generation induced by Brucella-activated T cells was completely abrogated when these cells were cultured with BMMs from IL-17 receptor knockout mice.", 
                            "tokens": [
                                "Although", 
                                "B.", 
                                "abortus-activated", 
                                "T", 
                                "cells", 
                                "actively", 
                                "secreted", 
                                "the", 
                                "pro-osteoclastogenic", 
                                "cytokines", 
                                "RANKL", 
                                "and", 
                                "IL-17", 
                                ",", 
                                "osteoclastogenesis", 
                                "depended", 
                                "on", 
                                "IL-17", 
                                ",", 
                                "because", 
                                "osteoclast", 
                                "generation", 
                                "induced", 
                                "by", 
                                "Brucella-activated", 
                                "T", 
                                "cells", 
                                "was", 
                                "completely", 
                                "abrogated", 
                                "when", 
                                "these", 
                                "cells", 
                                "were", 
                                "cultured", 
                                "with", 
                                "BMMs", 
                                "from", 
                                "IL-17", 
                                "receptor", 
                                "knockout", 
                                "mice", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Although B. abortus-activated T cells actively secreted the pro-osteoclastogenic cytokines RANKL and IL-17, osteoclastogenesis depended on IL-17, because osteoclast generation induced by Brucella-activated T cells was completely abrogated when these cells were cultured with BMMs from IL-17 receptor knockout mice. "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22867712", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 468, 
                    "offsetInEndSection": 758, 
                    "sentences": [
                        {
                            "text": " osteoclastogenesis and bone destruction in autoimmune arthritis.", 
                            "tokens": [
                                "osteoclastogenesis", 
                                "and", 
                                "bone", 
                                "destruction", 
                                "in", 
                                "autoimmune", 
                                "arthritis", 
                                "."
                            ]
                        }, 
                        {
                            "text": "We isolated human fibroblasts from RA, pyrophosphate arthropathy (PPA) and osteoarthritis (OA) patients and analyzed their RANKL/OPG expression profile and the capacity of their secreted factors to induce osteoclastogenesis.", 
                            "tokens": [
                                "We", 
                                "isolated", 
                                "human", 
                                "fibroblasts", 
                                "from", 
                                "RA", 
                                ",", 
                                "pyrophosphate", 
                                "arthropathy", 
                                "(", 
                                "PPA", 
                                ")", 
                                "and", 
                                "osteoarthritis", 
                                "(", 
                                "OA", 
                                ")", 
                                "patients", 
                                "and", 
                                "analyzed", 
                                "their", 
                                "RANKL/OPG", 
                                "expression", 
                                "profile", 
                                "and", 
                                "the", 
                                "capacity", 
                                "of", 
                                "their", 
                                "secreted", 
                                "factors", 
                                "to", 
                                "induce", 
                                "osteoclastogenesis", 
                                "."
                            ]
                        }
                    ], 
                    "text": " osteoclastogenesis and bone destruction in autoimmune arthritis. We isolated human fibroblasts from RA, pyrophosphate arthropathy (PPA) and osteoarthritis (OA) patients and analyzed their RANKL/OPG expression profile and the capacity of their secreted factors to induce osteoclastogenesis."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21618594", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 269, 
                    "offsetInEndSection": 478, 
                    "sentences": [
                        {
                            "text": "Osteoprotegerin (OPG) and receptor activator of nuclear factor \u03baB ligand (RANKL) are cytokines predominantly secreted by osteoblasts and play critical roles in the differentiation and function of osteoclasts.", 
                            "tokens": [
                                "Osteoprotegerin", 
                                "(", 
                                "OPG", 
                                ")", 
                                "and", 
                                "receptor", 
                                "activator", 
                                "of", 
                                "nuclear", 
                                "factor", 
                                "\u03baB", 
                                "ligand", 
                                "(", 
                                "RANKL", 
                                ")", 
                                "are", 
                                "cytokines", 
                                "predominantly", 
                                "secreted", 
                                "by", 
                                "osteoblasts", 
                                "and", 
                                "play", 
                                "critical", 
                                "roles", 
                                "in", 
                                "the", 
                                "differentiation", 
                                "and", 
                                "function", 
                                "of", 
                                "osteoclasts", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Osteoprotegerin (OPG) and receptor activator of nuclear factor \u03baB ligand (RANKL) are cytokines predominantly secreted by osteoblasts and play critical roles in the differentiation and function of osteoclasts. "
                }
            ], 
            "tokens": [
                "Is", 
                "RANKL", 
                "secreted", 
                "from", 
                "the", 
                "cells", 
                "?"
            ], 
            "triples": [], 
            "type": "yesno"
        }, 
        {
            "body": "Does metformin interfere thyroxine absorption?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008687", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013974", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000042"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23554450", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23264396", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23244059", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23154888", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23072197", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21748540", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21633823", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21435090", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21468525", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21041167"
            ], 
            "exact_answer": "", 
            "id": "51406e6223fec90375000009", 
            "ideal_answer": [
                "There are not reported data indicating that metformin interferes with thyroxine absorption"
            ], 
            "ranked": [], 
            "snippets": [], 
            "tokens": [
                "Does", 
                "metformin", 
                "interfere", 
                "thyroxine", 
                "absorption", 
                "?"
            ], 
            "triples": [], 
            "type": "yesno"
        }, 
        {
            "body": "Which thyroid hormone transporter is implicated in thyroid hormone resistance syndrome?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018382", 
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", 
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021", 
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042", 
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014284", 
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011815", 
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D060467", 
                "http://www.disease-ontology.org/api/metadata/DOID:11633", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0009914"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23392090", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22986150", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21459689", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18940949", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17574009", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17161330", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1422238", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8475937", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9092799", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21874823", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19541799", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12946875", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8115332", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17132274", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8594618", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17684393", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9350446", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8421095", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1580595", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7833674", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17040361", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2885829", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10687857"
            ], 
            "exact_answer": " Three syndromes, in which resistance to hormone action is respectively due to mutations in the gene encoding for thyroid hormone receptor TR\u03b2, impaired T4 and T3 transport, and impaired conversion of T4 to T3 mediated by deiodinases.One, producing severe psychomotor defects in > 100 males from 26 families, is caused by mutations in the cell-membrane transporter of TH, MCT8;AHDS thus represents a type of TH resistance caused by a defect in cellular TH transport.Hemizygous MCT8 mutations in males cause severe psychomotor retardation, known as the Allan-Herndon-Dudley syndrome (AHDS), and abnormal serum TH levels. One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects. One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects. One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects. One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects.", 
            "id": "52f8b2902059c6d71c000053", 
            "ideal_answer": "Hemizygous MCT8 mutations cuases TH resistance syndrome in males characterized by severe psychomotor retardation, known as the Allan-Herndon-Dudley syndrome (AHDS).", 
            "ranked": [
                " Three syndromes, in which resistance to hormone action is respectively due to mutations in the gene encoding for thyroid hormone receptor TR\u03b2, impaired T4 and T3 transport, and impaired conversion of T4 to T3 mediated by deiodinases.", 
                "One, producing severe psychomotor defects in > 100 males from 26 families, is caused by mutations in the cell-membrane transporter of TH, MCT8;", 
                "AHDS thus represents a type of TH resistance caused by a defect in cellular TH transport.", 
                "Hemizygous MCT8 mutations in males cause severe psychomotor retardation, known as the Allan-Herndon-Dudley syndrome (AHDS), and abnormal serum TH levels.", 
                " One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects.", 
                " One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects.", 
                " One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects.", 
                " One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects.", 
                " One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects.", 
                " One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects."
            ], 
            "snippets": [
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23392090", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 489, 
                    "offsetInEndSection": 732, 
                    "sentences": [
                        {
                            "text": "Hemizygous MCT8 mutations in males cause severe psychomotor retardation, known as the Allan-Herndon-Dudley syndrome (AHDS), and abnormal serum TH levels.", 
                            "tokens": [
                                "Hemizygous", 
                                "MCT8", 
                                "mutations", 
                                "in", 
                                "males", 
                                "cause", 
                                "severe", 
                                "psychomotor", 
                                "retardation", 
                                ",", 
                                "known", 
                                "as", 
                                "the", 
                                "Allan-Herndon-Dudley", 
                                "syndrome", 
                                "(", 
                                "AHDS", 
                                ")", 
                                ",", 
                                "and", 
                                "abnormal", 
                                "serum", 
                                "TH", 
                                "levels", 
                                "."
                            ]
                        }, 
                        {
                            "text": "AHDS thus represents a type of TH resistance caused by a defect in cellular TH transport.", 
                            "tokens": [
                                "AHDS", 
                                "thus", 
                                "represents", 
                                "a", 
                                "type", 
                                "of", 
                                "TH", 
                                "resistance", 
                                "caused", 
                                "by", 
                                "a", 
                                "defect", 
                                "in", 
                                "cellular", 
                                "TH", 
                                "transport", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Hemizygous MCT8 mutations in males cause severe psychomotor retardation, known as the Allan-Herndon-Dudley syndrome (AHDS), and abnormal serum TH levels. AHDS thus represents a type of TH resistance caused by a defect in cellular TH transport."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22986150", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 720, 
                    "offsetInEndSection": 832, 
                    "sentences": [
                        {
                            "text": " One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects.", 
                            "tokens": [
                                "One", 
                                "of", 
                                "them", 
                                ",", 
                                "caused", 
                                "by", 
                                "mutations", 
                                "in", 
                                "the", 
                                "TH", 
                                "cell-membrane", 
                                "transporter", 
                                "MCT8", 
                                ",", 
                                "produces", 
                                "severe", 
                                "psychomotor", 
                                "defects", 
                                "."
                            ]
                        }
                    ], 
                    "text": " One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21459689", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 137, 
                    "offsetInEndSection": 371, 
                    "sentences": [
                        {
                            "text": " Three syndromes, in which resistance to hormone action is respectively due to mutations in the gene encoding for thyroid hormone receptor TR\u03b2, impaired T4 and T3 transport, and impaired conversion of T4 to T3 mediated by deiodinases.", 
                            "tokens": [
                                "Three", 
                                "syndromes", 
                                ",", 
                                "in", 
                                "which", 
                                "resistance", 
                                "to", 
                                "hormone", 
                                "action", 
                                "is", 
                                "respectively", 
                                "due", 
                                "to", 
                                "mutations", 
                                "in", 
                                "the", 
                                "gene", 
                                "encoding", 
                                "for", 
                                "thyroid", 
                                "hormone", 
                                "receptor", 
                                "TR\u03b2", 
                                ",", 
                                "impaired", 
                                "T4", 
                                "and", 
                                "T3", 
                                "transport", 
                                ",", 
                                "and", 
                                "impaired", 
                                "conversion", 
                                "of", 
                                "T4", 
                                "to", 
                                "T3", 
                                "mediated", 
                                "by", 
                                "deiodinases", 
                                "."
                            ]
                        }
                    ], 
                    "text": " Three syndromes, in which resistance to hormone action is respectively due to mutations in the gene encoding for thyroid hormone receptor TR\u03b2, impaired T4 and T3 transport, and impaired conversion of T4 to T3 mediated by deiodinases."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17574009", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 585, 
                    "offsetInEndSection": 728, 
                    "sentences": [
                        {
                            "text": "One, producing severe psychomotor defects in > 100 males from 26 families, is caused by mutations in the cell-membrane transporter of TH, MCT8;", 
                            "tokens": [
                                "One", 
                                ",", 
                                "producing", 
                                "severe", 
                                "psychomotor", 
                                "defects", 
                                "in", 
                                ">", 
                                "100", 
                                "males", 
                                "from", 
                                "26", 
                                "families", 
                                ",", 
                                "is", 
                                "caused", 
                                "by", 
                                "mutations", 
                                "in", 
                                "the", 
                                "cell-membrane", 
                                "transporter", 
                                "of", 
                                "TH", 
                                ",", 
                                "MCT8", 
                                ";"
                            ]
                        }
                    ], 
                    "text": "One, producing severe psychomotor defects in > 100 males from 26 families, is caused by mutations in the cell-membrane transporter of TH, MCT8;"
                }
            ], 
            "tokens": [
                "Which", 
                "thyroid", 
                "hormone", 
                "transporter", 
                "is", 
                "implicated", 
                "in", 
                "thyroid", 
                "hormone", 
                "resistance", 
                "syndrome", 
                "?"
            ], 
            "triples": [], 
            "type": "factoid"
        }, 
        {
            "body": "Which miRNAs could be used as potential biomarkers for epithelial ovarian cancer?", 
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:2394", 
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010051", 
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683", 
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015415"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23978303", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23918241", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23888941", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23836287", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23621186", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23542579", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23272653", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22246341", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21971665", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21571355", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21345725", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20035894", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19074899", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18954897"
            ], 
            "exact_answer": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancerPrognostic implications of microRNA-100 and its functional roles in             human epithelial ovarian cancerMicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management our results strongly suggest that let-7i might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response and survival in patients with ovarian cancerFinally, five promising differentially miRNAs (miR-200a, miR-100, miR-141, miR-200b, and miR-200c) were reported with the consistent direction in four or more studies.In this study, we demonstrated that miR-200a and E-cadherin were significantly upregulated in EOC compared to benign epithelial ovarian cysts and normal ovarian tissuesUpregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancerThey may be novel biomarkers for early detection or therapeutic targets of ovarian             cancerOur results suggest that miRNAs may play a role in the progression of OSC, and miR-510 and miR-509-5p may be considered novel-candidate clinical biomarkers for predicting OSC outcome", 
            "id": "553fa78b1d53b76422000007", 
            "ideal_answer": [
                "miR-200a, miR-100, miR-141, miR-200b, miR-200c, miR-203, miR-510, miR-509-5p, miR-132, miR-26a, let-7b, miR-145, miR-182, miR-152, miR-148a, let-7a, let-7i, miR-21, miR-92 and miR-93 could be used as potential biomarkers for epithelial ovarian cancer."
            ], 
            "ranked": [
                "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer", 
                "Prognostic implications of microRNA-100 and its functional roles in             human epithelial ovarian cancer", 
                "MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management", 
                " our results strongly suggest that let-7i might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response and survival in patients with ovarian cancer", 
                "Finally, five promising differentially miRNAs (miR-200a, miR-100, miR-141, miR-200b, and miR-200c) were reported with the consistent direction in four or more studies.", 
                "In this study, we demonstrated that miR-200a and E-cadherin were significantly upregulated in EOC compared to benign epithelial ovarian cysts and normal ovarian tissues", 
                "Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer", 
                "They may be novel biomarkers for early detection or therapeutic targets of ovarian             cancer", 
                "Our results suggest that miRNAs may play a role in the progression of OSC, and miR-510 and miR-509-5p may be considered novel-candidate clinical biomarkers for predicting OSC outcome", 
                "miRNAs-21, 92 and 93 are known oncogenes with therapeutic and biomarker potential"
            ], 
            "snippets": [
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23978303", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1010, 
                    "offsetInEndSection": 1388, 
                    "sentences": [
                        {
                            "text": "Finally, five promising differentially miRNAs (miR-200a, miR-100, miR-141, miR-200b, and miR-200c) were reported with the consistent direction in four or more studies.", 
                            "tokens": [
                                "Finally", 
                                ",", 
                                "five", 
                                "promising", 
                                "differentially", 
                                "miRNAs", 
                                "(", 
                                "miR-200a", 
                                ",", 
                                "miR-100", 
                                ",", 
                                "miR-141", 
                                ",", 
                                "miR-200b", 
                                ",", 
                                "and", 
                                "miR-200c", 
                                ")", 
                                "were", 
                                "reported", 
                                "with", 
                                "the", 
                                "consistent", 
                                "direction", 
                                "in", 
                                "four", 
                                "or", 
                                "more", 
                                "studies", 
                                "."
                            ]
                        }, 
                        {
                            "text": "MiR-200a, miR-200b, miR-200c, and miR-141, all of them belong to miR-200 family, were reported with consistently up-regulated in at least 4 studies, whereas miR-100 was reported with down-regulated in 4 studies", 
                            "tokens": [
                                "MiR-200a", 
                                ",", 
                                "miR-200b", 
                                ",", 
                                "miR-200c", 
                                ",", 
                                "and", 
                                "miR-141", 
                                ",", 
                                "all", 
                                "of", 
                                "them", 
                                "belong", 
                                "to", 
                                "miR-200", 
                                "family", 
                                ",", 
                                "were", 
                                "reported", 
                                "with", 
                                "consistently", 
                                "up-regulated", 
                                "in", 
                                "at", 
                                "least", 
                                "4", 
                                "studies", 
                                ",", 
                                "whereas", 
                                "miR-100", 
                                "was", 
                                "reported", 
                                "with", 
                                "down-regulated", 
                                "in", 
                                "4", 
                                "studies"
                            ]
                        }
                    ], 
                    "text": "Finally, five promising differentially miRNAs (miR-200a, miR-100, miR-141, miR-200b, and miR-200c) were reported with the consistent direction in four or more studies. MiR-200a, miR-200b, miR-200c, and miR-141, all of them belong to miR-200 family, were reported with consistently up-regulated in at least 4 studies, whereas miR-100 was reported with down-regulated in 4 studies"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918241", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 122, 
                    "sentences": [
                        {
                            "text": "Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer", 
                            "tokens": [
                                "Upregulation", 
                                "of", 
                                "microRNA-203", 
                                "is", 
                                "associated", 
                                "with", 
                                "advanced", 
                                "tumor", 
                                "progression", 
                                "and", 
                                "poor", 
                                "prognosis", 
                                "in", 
                                "epithelial", 
                                "ovarian", 
                                "cancer"
                            ]
                        }
                    ], 
                    "text": "Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918241", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1036, 
                    "offsetInEndSection": 1418, 
                    "sentences": [
                        {
                            "text": "multivariate analysis showed that the status of miR-203 expression was an independent predictor for both overall survival and progression-free survival in EOC.", 
                            "tokens": [
                                "multivariate", 
                                "analysis", 
                                "showed", 
                                "that", 
                                "the", 
                                "status", 
                                "of", 
                                "miR-203", 
                                "expression", 
                                "was", 
                                "an", 
                                "independent", 
                                "predictor", 
                                "for", 
                                "both", 
                                "overall", 
                                "survival", 
                                "and", 
                                "progression-free", 
                                "survival", 
                                "in", 
                                "EOC", 
                                "."
                            ]
                        }, 
                        {
                            "text": "These findings provide the convincing evidence for the first time that the upregulation of miR-203 may serve as a novel molecular marker to predict the aggressive tumor progression and unfavorable prognosis of EOC patients", 
                            "tokens": [
                                "These", 
                                "findings", 
                                "provide", 
                                "the", 
                                "convincing", 
                                "evidence", 
                                "for", 
                                "the", 
                                "first", 
                                "time", 
                                "that", 
                                "the", 
                                "upregulation", 
                                "of", 
                                "miR-203", 
                                "may", 
                                "serve", 
                                "as", 
                                "a", 
                                "novel", 
                                "molecular", 
                                "marker", 
                                "to", 
                                "predict", 
                                "the", 
                                "aggressive", 
                                "tumor", 
                                "progression", 
                                "and", 
                                "unfavorable", 
                                "prognosis", 
                                "of", 
                                "EOC", 
                                "patients"
                            ]
                        }
                    ], 
                    "text": "multivariate analysis showed that the status of miR-203 expression was an independent predictor for both overall survival and progression-free survival in EOC. These findings provide the convincing evidence for the first time that the upregulation of miR-203 may serve as a novel molecular marker to predict the aggressive tumor progression and unfavorable prognosis of EOC patients"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23888941", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 493, 
                    "offsetInEndSection": 773, 
                    "sentences": [
                        {
                            "text": "Some, but not all, of the data indicated that the miR-200 family was dysregulated in a variety of malignancies.", 
                            "tokens": [
                                "Some", 
                                ",", 
                                "but", 
                                "not", 
                                "all", 
                                ",", 
                                "of", 
                                "the", 
                                "data", 
                                "indicated", 
                                "that", 
                                "the", 
                                "miR-200", 
                                "family", 
                                "was", 
                                "dysregulated", 
                                "in", 
                                "a", 
                                "variety", 
                                "of", 
                                "malignancies", 
                                "."
                            ]
                        }, 
                        {
                            "text": "In this study, we demonstrated that miR-200a and E-cadherin were significantly upregulated in EOC compared to benign epithelial ovarian cysts and normal ovarian tissues", 
                            "tokens": [
                                "In", 
                                "this", 
                                "study", 
                                ",", 
                                "we", 
                                "demonstrated", 
                                "that", 
                                "miR-200a", 
                                "and", 
                                "E-cadherin", 
                                "were", 
                                "significantly", 
                                "upregulated", 
                                "in", 
                                "EOC", 
                                "compared", 
                                "to", 
                                "benign", 
                                "epithelial", 
                                "ovarian", 
                                "cysts", 
                                "and", 
                                "normal", 
                                "ovarian", 
                                "tissues"
                            ]
                        }
                    ], 
                    "text": "Some, but not all, of the data indicated that the miR-200 family was dysregulated in a variety of malignancies. In this study, we demonstrated that miR-200a and E-cadherin were significantly upregulated in EOC compared to benign epithelial ovarian cysts and normal ovarian tissues"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23888941", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1324, 
                    "offsetInEndSection": 1656, 
                    "sentences": [
                        {
                            "text": "There was a significantly positive correlation between miR-200a and E-cadherin in EOC.", 
                            "tokens": [
                                "There", 
                                "was", 
                                "a", 
                                "significantly", 
                                "positive", 
                                "correlation", 
                                "between", 
                                "miR-200a", 
                                "and", 
                                "E-cadherin", 
                                "in", 
                                "EOC", 
                                "."
                            ]
                        }, 
                        {
                            "text": "The biphasic expression pattern suggested that miR-200a levels may serve as novel biomarkers for the early detection of EOC, and miR-200a and E-cadherin are candidate targets for the development of new treatment modalities against ovarian cancer", 
                            "tokens": [
                                "The", 
                                "biphasic", 
                                "expression", 
                                "pattern", 
                                "suggested", 
                                "that", 
                                "miR-200a", 
                                "levels", 
                                "may", 
                                "serve", 
                                "as", 
                                "novel", 
                                "biomarkers", 
                                "for", 
                                "the", 
                                "early", 
                                "detection", 
                                "of", 
                                "EOC", 
                                ",", 
                                "and", 
                                "miR-200a", 
                                "and", 
                                "E-cadherin", 
                                "are", 
                                "candidate", 
                                "targets", 
                                "for", 
                                "the", 
                                "development", 
                                "of", 
                                "new", 
                                "treatment", 
                                "modalities", 
                                "against", 
                                "ovarian", 
                                "cancer"
                            ]
                        }
                    ], 
                    "text": "There was a significantly positive correlation between miR-200a and E-cadherin in EOC. The biphasic expression pattern suggested that miR-200a levels may serve as novel biomarkers for the early detection of EOC, and miR-200a and E-cadherin are candidate targets for the development of new treatment modalities against ovarian cancer"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836287", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1385, 
                    "offsetInEndSection": 1771, 
                    "sentences": [
                        {
                            "text": "Kaplan-Meier analysis showed low miR-510 expression, low miR-509-5p expression, and advanced FIGO stage, and chemotherapy resistance were significantly associated with poorer overall survival (P < 0.05).", 
                            "tokens": [
                                "Kaplan-Meier", 
                                "analysis", 
                                "showed", 
                                "low", 
                                "miR-510", 
                                "expression", 
                                ",", 
                                "low", 
                                "miR-509-5p", 
                                "expression", 
                                ",", 
                                "and", 
                                "advanced", 
                                "FIGO", 
                                "stage", 
                                ",", 
                                "and", 
                                "chemotherapy", 
                                "resistance", 
                                "were", 
                                "significantly", 
                                "associated", 
                                "with", 
                                "poorer", 
                                "overall", 
                                "survival", 
                                "(", 
                                "P", 
                                "<", 
                                "0.05", 
                                ")", 
                                "."
                            ]
                        }, 
                        {
                            "text": "Our results suggest that miRNAs may play a role in the progression of OSC, and miR-510 and miR-509-5p may be considered novel-candidate clinical biomarkers for predicting OSC outcome", 
                            "tokens": [
                                "Our", 
                                "results", 
                                "suggest", 
                                "that", 
                                "miRNAs", 
                                "may", 
                                "play", 
                                "a", 
                                "role", 
                                "in", 
                                "the", 
                                "progression", 
                                "of", 
                                "OSC", 
                                ",", 
                                "and", 
                                "miR-510", 
                                "and", 
                                "miR-509-5p", 
                                "may", 
                                "be", 
                                "considered", 
                                "novel-candidate", 
                                "clinical", 
                                "biomarkers", 
                                "for", 
                                "predicting", 
                                "OSC", 
                                "outcome"
                            ]
                        }
                    ], 
                    "text": "Kaplan-Meier analysis showed low miR-510 expression, low miR-509-5p expression, and advanced FIGO stage, and chemotherapy resistance were significantly associated with poorer overall survival (P < 0.05). Our results suggest that miRNAs may play a role in the progression of OSC, and miR-510 and miR-509-5p may be considered novel-candidate clinical biomarkers for predicting OSC outcome"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836287", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1158, 
                    "offsetInEndSection": 1383, 
                    "sentences": [
                        {
                            "text": "The qRT-PCR results showed that miR-510, miR-509-5p, and miR-508-3p were significantly downregulated and that miR-483-5p was upregulated in stage III OSC compared with stage I, which was consistent with the microarray results", 
                            "tokens": [
                                "The", 
                                "qRT-PCR", 
                                "results", 
                                "showed", 
                                "that", 
                                "miR-510", 
                                ",", 
                                "miR-509-5p", 
                                ",", 
                                "and", 
                                "miR-508-3p", 
                                "were", 
                                "significantly", 
                                "downregulated", 
                                "and", 
                                "that", 
                                "miR-483-5p", 
                                "was", 
                                "upregulated", 
                                "in", 
                                "stage", 
                                "III", 
                                "OSC", 
                                "compared", 
                                "with", 
                                "stage", 
                                "I", 
                                ",", 
                                "which", 
                                "was", 
                                "consistent", 
                                "with", 
                                "the", 
                                "microarray", 
                                "results"
                            ]
                        }
                    ], 
                    "text": "The qRT-PCR results showed that miR-510, miR-509-5p, and miR-508-3p were significantly downregulated and that miR-483-5p was upregulated in stage III OSC compared with stage I, which was consistent with the microarray results"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23621186", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 138, 
                    "offsetInEndSection": 704, 
                    "sentences": [
                        {
                            "text": "In this study, we examined serum miR-21 levels in epithelial ovarian cancer (EOC) patients, and explored its association with clinicopathological factors and prognosis.", 
                            "tokens": [
                                "In", 
                                "this", 
                                "study", 
                                ",", 
                                "we", 
                                "examined", 
                                "serum", 
                                "miR-21", 
                                "levels", 
                                "in", 
                                "epithelial", 
                                "ovarian", 
                                "cancer", 
                                "(", 
                                "EOC", 
                                ")", 
                                "patients", 
                                ",", 
                                "and", 
                                "explored", 
                                "its", 
                                "association", 
                                "with", 
                                "clinicopathological", 
                                "factors", 
                                "and", 
                                "prognosis", 
                                "."
                            ]
                        }, 
                        {
                            "text": "The results showed significantly higher serum miR-21 levels in EOC patients than in healthy controls.", 
                            "tokens": [
                                "The", 
                                "results", 
                                "showed", 
                                "significantly", 
                                "higher", 
                                "serum", 
                                "miR-21", 
                                "levels", 
                                "in", 
                                "EOC", 
                                "patients", 
                                "than", 
                                "in", 
                                "healthy", 
                                "controls", 
                                "."
                            ]
                        }, 
                        {
                            "text": "In addition, increased serum miR-21 expression was correlated with advanced FIGO stage, high tumor grade, and shortened overall survival.", 
                            "tokens": [
                                "In", 
                                "addition", 
                                ",", 
                                "increased", 
                                "serum", 
                                "miR-21", 
                                "expression", 
                                "was", 
                                "correlated", 
                                "with", 
                                "advanced", 
                                "FIGO", 
                                "stage", 
                                ",", 
                                "high", 
                                "tumor", 
                                "grade", 
                                ",", 
                                "and", 
                                "shortened", 
                                "overall", 
                                "survival", 
                                "."
                            ]
                        }, 
                        {
                            "text": "These findings indicate that serum miR-21 may serve as a novel diagnostic and prognostic marker, and be used as a therapeutic target for the treatment of EOC", 
                            "tokens": [
                                "These", 
                                "findings", 
                                "indicate", 
                                "that", 
                                "serum", 
                                "miR-21", 
                                "may", 
                                "serve", 
                                "as", 
                                "a", 
                                "novel", 
                                "diagnostic", 
                                "and", 
                                "prognostic", 
                                "marker", 
                                ",", 
                                "and", 
                                "be", 
                                "used", 
                                "as", 
                                "a", 
                                "therapeutic", 
                                "target", 
                                "for", 
                                "the", 
                                "treatment", 
                                "of", 
                                "EOC"
                            ]
                        }
                    ], 
                    "text": "In this study, we examined serum miR-21 levels in epithelial ovarian cancer (EOC) patients, and explored its association with clinicopathological factors and prognosis. The results showed significantly higher serum miR-21 levels in EOC patients than in healthy controls. In addition, increased serum miR-21 expression was correlated with advanced FIGO stage, high tumor grade, and shortened overall survival. These findings indicate that serum miR-21 may serve as a novel diagnostic and prognostic marker, and be used as a therapeutic target for the treatment of EOC"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23621186", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 119, 
                    "sentences": [
                        {
                            "text": "Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer", 
                            "tokens": [
                                "Identification", 
                                "of", 
                                "serum", 
                                "microRNA-21", 
                                "as", 
                                "a", 
                                "biomarker", 
                                "for", 
                                "early", 
                                "detection", 
                                "and", 
                                "prognosis", 
                                "in", 
                                "human", 
                                "epithelial", 
                                "ovarian", 
                                "cancer"
                            ]
                        }
                    ], 
                    "text": "Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542579", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1680, 
                    "offsetInEndSection": 1813, 
                    "sentences": [
                        {
                            "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer.", 
                            "tokens": [
                                "Serum", 
                                "miR-132", 
                                ",", 
                                "miR-26a", 
                                ",", 
                                "let-7b", 
                                ",", 
                                "and", 
                                "miR-145", 
                                "could", 
                                "be", 
                                "considered", 
                                "as", 
                                "potential", 
                                "candidates", 
                                "as", 
                                "novel", 
                                "biomarkers", 
                                "in", 
                                "serous", 
                                "ovarian", 
                                "cancer", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542579", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1173, 
                    "offsetInEndSection": 1665, 
                    "sentences": [
                        {
                            "text": "Among the miRNAs that showed a consistent regulation tendency through all specimens and showed more than a 2-fold difference in serum, 5 miRNAs (miR-132, miR-26a, let-7b, miR-145, and miR-143) were determined as the 5 most markedly down-regulated miRNAs in the serum from ovarian cancer patients with respect to those of controls.", 
                            "tokens": [
                                "Among", 
                                "the", 
                                "miRNAs", 
                                "that", 
                                "showed", 
                                "a", 
                                "consistent", 
                                "regulation", 
                                "tendency", 
                                "through", 
                                "all", 
                                "specimens", 
                                "and", 
                                "showed", 
                                "more", 
                                "than", 
                                "a", 
                                "2-fold", 
                                "difference", 
                                "in", 
                                "serum", 
                                ",", 
                                "5", 
                                "miRNAs", 
                                "(", 
                                "miR-132", 
                                ",", 
                                "miR-26a", 
                                ",", 
                                "let-7b", 
                                ",", 
                                "miR-145", 
                                ",", 
                                "and", 
                                "miR-143", 
                                ")", 
                                "were", 
                                "determined", 
                                "as", 
                                "the", 
                                "5", 
                                "most", 
                                "markedly", 
                                "down-regulated", 
                                "miRNAs", 
                                "in", 
                                "the", 
                                "serum", 
                                "from", 
                                "ovarian", 
                                "cancer", 
                                "patients", 
                                "with", 
                                "respect", 
                                "to", 
                                "those", 
                                "of", 
                                "controls", 
                                "."
                            ]
                        }, 
                        {
                            "text": "Four miRNAs (miR-132, miR-26a, let-7b, and miR-145) out of 5 selected miRNAs were significantly underexpressed in the serum of ovarian cancer patients in qRT-PCR", 
                            "tokens": [
                                "Four", 
                                "miRNAs", 
                                "(", 
                                "miR-132", 
                                ",", 
                                "miR-26a", 
                                ",", 
                                "let-7b", 
                                ",", 
                                "and", 
                                "miR-145", 
                                ")", 
                                "out", 
                                "of", 
                                "5", 
                                "selected", 
                                "miRNAs", 
                                "were", 
                                "significantly", 
                                "underexpressed", 
                                "in", 
                                "the", 
                                "serum", 
                                "of", 
                                "ovarian", 
                                "cancer", 
                                "patients", 
                                "in", 
                                "qRT-PCR"
                            ]
                        }
                    ], 
                    "text": "Among the miRNAs that showed a consistent regulation tendency through all specimens and showed more than a 2-fold difference in serum, 5 miRNAs (miR-132, miR-26a, let-7b, miR-145, and miR-143) were determined as the 5 most markedly down-regulated miRNAs in the serum from ovarian cancer patients with respect to those of controls. Four miRNAs (miR-132, miR-26a, let-7b, and miR-145) out of 5 selected miRNAs were significantly underexpressed in the serum of ovarian cancer patients in qRT-PCR"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23272653", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 739, 
                    "offsetInEndSection": 968, 
                    "sentences": [
                        {
                            "text": " microRNA (miR)-182, miR-200a, miR-200b and miR-200c were highly overexpressed in the SEOC cell lines relative to normal human ovarian surface epithelial cells and were assessed in RNA extracted from serum as candidate biomarkers", 
                            "tokens": [
                                "microRNA", 
                                "(", 
                                "miR", 
                                ")", 
                                "-182", 
                                ",", 
                                "miR-200a", 
                                ",", 
                                "miR-200b", 
                                "and", 
                                "miR-200c", 
                                "were", 
                                "highly", 
                                "overexpressed", 
                                "in", 
                                "the", 
                                "SEOC", 
                                "cell", 
                                "lines", 
                                "relative", 
                                "to", 
                                "normal", 
                                "human", 
                                "ovarian", 
                                "surface", 
                                "epithelial", 
                                "cells", 
                                "and", 
                                "were", 
                                "assessed", 
                                "in", 
                                "RNA", 
                                "extracted", 
                                "from", 
                                "serum", 
                                "as", 
                                "candidate", 
                                "biomarkers"
                            ]
                        }
                    ], 
                    "text": " microRNA (miR)-182, miR-200a, miR-200b and miR-200c were highly overexpressed in the SEOC cell lines relative to normal human ovarian surface epithelial cells and were assessed in RNA extracted from serum as candidate biomarkers"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22246341", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1426, 
                    "offsetInEndSection": 1633, 
                    "sentences": [
                        {
                            "text": "Together, these results suggest that low miR-100 expression             may be an independent poor prognostic factor and miR-100 can function as a tumor             suppressor by targeting PLK1 in human EOCs", 
                            "tokens": [
                                "Together", 
                                ",", 
                                "these", 
                                "results", 
                                "suggest", 
                                "that", 
                                "low", 
                                "miR-100", 
                                "expression", 
                                "may", 
                                "be", 
                                "an", 
                                "independent", 
                                "poor", 
                                "prognostic", 
                                "factor", 
                                "and", 
                                "miR-100", 
                                "can", 
                                "function", 
                                "as", 
                                "a", 
                                "tumor", 
                                "suppressor", 
                                "by", 
                                "targeting", 
                                "PLK1", 
                                "in", 
                                "human", 
                                "EOCs"
                            ]
                        }
                    ], 
                    "text": "Together, these results suggest that low miR-100 expression             may be an independent poor prognostic factor and miR-100 can function as a tumor             suppressor by targeting PLK1 in human EOCs"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22246341", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 111, 
                    "sentences": [
                        {
                            "text": "Prognostic implications of microRNA-100 and its functional roles in             human epithelial ovarian cancer", 
                            "tokens": [
                                "Prognostic", 
                                "implications", 
                                "of", 
                                "microRNA-100", 
                                "and", 
                                "its", 
                                "functional", 
                                "roles", 
                                "in", 
                                "human", 
                                "epithelial", 
                                "ovarian", 
                                "cancer"
                            ]
                        }
                    ], 
                    "text": "Prognostic implications of microRNA-100 and its functional roles in             human epithelial ovarian cancer"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21971665", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1476, 
                    "offsetInEndSection": 1738, 
                    "sentences": [
                        {
                            "text": "Taken together, miR-152 and miR-148a may be involved             in the carcinogenesis of ovarian cancer through deregulation of cell proliferation.", 
                            "tokens": [
                                "Taken", 
                                "together", 
                                ",", 
                                "miR-152", 
                                "and", 
                                "miR-148a", 
                                "may", 
                                "be", 
                                "involved", 
                                "in", 
                                "the", 
                                "carcinogenesis", 
                                "of", 
                                "ovarian", 
                                "cancer", 
                                "through", 
                                "deregulation", 
                                "of", 
                                "cell", 
                                "proliferation", 
                                "."
                            ]
                        }, 
                        {
                            "text": "They may be novel biomarkers for early detection or therapeutic targets of ovarian             cancer", 
                            "tokens": [
                                "They", 
                                "may", 
                                "be", 
                                "novel", 
                                "biomarkers", 
                                "for", 
                                "early", 
                                "detection", 
                                "or", 
                                "therapeutic", 
                                "targets", 
                                "of", 
                                "ovarian", 
                                "cancer"
                            ]
                        }
                    ], 
                    "text": "Taken together, miR-152 and miR-148a may be involved             in the carcinogenesis of ovarian cancer through deregulation of cell proliferation.             They may be novel biomarkers for early detection or therapeutic targets of ovarian             cancer"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21571355", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 92, 
                    "sentences": [
                        {
                            "text": "MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management", 
                            "tokens": [
                                "MicroRNA", 
                                "let-7a", 
                                ":", 
                                "a", 
                                "potential", 
                                "marker", 
                                "for", 
                                "selection", 
                                "of", 
                                "paclitaxel", 
                                "in", 
                                "ovarian", 
                                "cancer", 
                                "management"
                            ]
                        }
                    ], 
                    "text": "MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21571355", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1988, 
                    "offsetInEndSection": 2236, 
                    "sentences": [
                        {
                            "text": " The study suggests that the beneficial impact of the addition of paclitaxel on EOC survival was significantly linked to let-7a levels, and that miRNAs such as let-7a may be a useful marker for selection of chemotherapeutic agents in EOC management", 
                            "tokens": [
                                "The", 
                                "study", 
                                "suggests", 
                                "that", 
                                "the", 
                                "beneficial", 
                                "impact", 
                                "of", 
                                "the", 
                                "addition", 
                                "of", 
                                "paclitaxel", 
                                "on", 
                                "EOC", 
                                "survival", 
                                "was", 
                                "significantly", 
                                "linked", 
                                "to", 
                                "let-7a", 
                                "levels", 
                                ",", 
                                "and", 
                                "that", 
                                "miRNAs", 
                                "such", 
                                "as", 
                                "let-7a", 
                                "may", 
                                "be", 
                                "a", 
                                "useful", 
                                "marker", 
                                "for", 
                                "selection", 
                                "of", 
                                "chemotherapeutic", 
                                "agents", 
                                "in", 
                                "EOC", 
                                "management"
                            ]
                        }
                    ], 
                    "text": " The study suggests that the beneficial impact of the addition of paclitaxel on EOC survival was significantly linked to let-7a levels, and that miRNAs such as let-7a may be a useful marker for selection of chemotherapeutic agents in EOC management"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21345725", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 2573, 
                    "offsetInEndSection": 2669, 
                    "sentences": [
                        {
                            "text": "miR-200c has potential as a predictor of survival, and is a biomarker of relapse, in stage I EOC", 
                            "tokens": [
                                "miR-200c", 
                                "has", 
                                "potential", 
                                "as", 
                                "a", 
                                "predictor", 
                                "of", 
                                "survival", 
                                ",", 
                                "and", 
                                "is", 
                                "a", 
                                "biomarker", 
                                "of", 
                                "relapse", 
                                ",", 
                                "in", 
                                "stage", 
                                "I", 
                                "EOC"
                            ]
                        }
                    ], 
                    "text": "miR-200c has potential as a predictor of survival, and is a biomarker of relapse, in stage I EOC"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074899", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 116, 
                    "sentences": [
                        {
                            "text": "MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer", 
                            "tokens": [
                                "MicroRNA", 
                                "microarray", 
                                "identifies", 
                                "Let-7i", 
                                "as", 
                                "a", 
                                "novel", 
                                "biomarker", 
                                "and", 
                                "therapeutic", 
                                "target", 
                                "in", 
                                "human", 
                                "epithelial", 
                                "ovarian", 
                                "cancer"
                            ]
                        }
                    ], 
                    "text": "MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074899", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1507, 
                    "offsetInEndSection": 1723, 
                    "sentences": [
                        {
                            "text": " our results strongly suggest that let-7i might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response and survival in patients with ovarian cancer", 
                            "tokens": [
                                "our", 
                                "results", 
                                "strongly", 
                                "suggest", 
                                "that", 
                                "let-7i", 
                                "might", 
                                "be", 
                                "used", 
                                "as", 
                                "a", 
                                "therapeutic", 
                                "target", 
                                "to", 
                                "modulate", 
                                "platinum-based", 
                                "chemotherapy", 
                                "and", 
                                "as", 
                                "a", 
                                "biomarker", 
                                "to", 
                                "predict", 
                                "chemotherapy", 
                                "response", 
                                "and", 
                                "survival", 
                                "in", 
                                "patients", 
                                "with", 
                                "ovarian", 
                                "cancer"
                            ]
                        }
                    ], 
                    "text": " our results strongly suggest that let-7i might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response and survival in patients with ovarian cancer"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18954897", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1560, 
                    "offsetInEndSection": 1641, 
                    "sentences": [
                        {
                            "text": "miRNAs-21, 92 and 93 are known oncogenes with therapeutic and biomarker potential", 
                            "tokens": [
                                "miRNAs-21", 
                                ",", 
                                "92", 
                                "and", 
                                "93", 
                                "are", 
                                "known", 
                                "oncogenes", 
                                "with", 
                                "therapeutic", 
                                "and", 
                                "biomarker", 
                                "potential"
                            ]
                        }
                    ], 
                    "text": "miRNAs-21, 92 and 93 are known oncogenes with therapeutic and biomarker potential"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542579", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1641, 
                    "offsetInEndSection": 1773, 
                    "sentences": [
                        {
                            "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer", 
                            "tokens": [
                                "Serum", 
                                "miR-132", 
                                ",", 
                                "miR-26a", 
                                ",", 
                                "let-7b", 
                                ",", 
                                "and", 
                                "miR-145", 
                                "could", 
                                "be", 
                                "considered", 
                                "as", 
                                "potential", 
                                "candidates", 
                                "as", 
                                "novel", 
                                "biomarkers", 
                                "in", 
                                "serous", 
                                "ovarian", 
                                "cancer"
                            ]
                        }
                    ], 
                    "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542579", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1641, 
                    "offsetInEndSection": 1773, 
                    "sentences": [
                        {
                            "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer", 
                            "tokens": [
                                "Serum", 
                                "miR-132", 
                                ",", 
                                "miR-26a", 
                                ",", 
                                "let-7b", 
                                ",", 
                                "and", 
                                "miR-145", 
                                "could", 
                                "be", 
                                "considered", 
                                "as", 
                                "potential", 
                                "candidates", 
                                "as", 
                                "novel", 
                                "biomarkers", 
                                "in", 
                                "serous", 
                                "ovarian", 
                                "cancer"
                            ]
                        }
                    ], 
                    "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542579", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1641, 
                    "offsetInEndSection": 1773, 
                    "sentences": [
                        {
                            "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer", 
                            "tokens": [
                                "Serum", 
                                "miR-132", 
                                ",", 
                                "miR-26a", 
                                ",", 
                                "let-7b", 
                                ",", 
                                "and", 
                                "miR-145", 
                                "could", 
                                "be", 
                                "considered", 
                                "as", 
                                "potential", 
                                "candidates", 
                                "as", 
                                "novel", 
                                "biomarkers", 
                                "in", 
                                "serous", 
                                "ovarian", 
                                "cancer"
                            ]
                        }
                    ], 
                    "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer"
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542579", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1641, 
                    "offsetInEndSection": 1773, 
                    "sentences": [
                        {
                            "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer", 
                            "tokens": [
                                "Serum", 
                                "miR-132", 
                                ",", 
                                "miR-26a", 
                                ",", 
                                "let-7b", 
                                ",", 
                                "and", 
                                "miR-145", 
                                "could", 
                                "be", 
                                "considered", 
                                "as", 
                                "potential", 
                                "candidates", 
                                "as", 
                                "novel", 
                                "biomarkers", 
                                "in", 
                                "serous", 
                                "ovarian", 
                                "cancer"
                            ]
                        }
                    ], 
                    "text": "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer"
                }
            ], 
            "tokens": [
                "Which", 
                "miRNAs", 
                "could", 
                "be", 
                "used", 
                "as", 
                "potential", 
                "biomarkers", 
                "for", 
                "epithelial", 
                "ovarian", 
                "cancer", 
                "?"
            ], 
            "triples": [], 
            "type": "list"
        }, 
        {
            "body": "Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009157", 
                "http://www.disease-ontology.org/api/metadata/DOID:437", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002800", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000110", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004791"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21328290", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21133188", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20663605", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15610702", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21845054"
            ], 
            "exact_answer": "Acetylcholinesterase inhibitors provide temporary, symptomatic treatment for all forms of myasthenia gravis.Pyridostigmine is the most widely used acetylcholinesterase inhibitor.Response to acetylcholinesterase inhibitors in observational studies is so clear that a randomised controlled trial depriving participants in the placebo arm of treatment would be difficult to justify.The switch to SR-Pyr ameliorated the total quantified myasthenia gravis (QMG) score from 0.9 \u00b1 0.5 to 0.6 \u00b1 0.4 (p<0.001) in all patients and in the younger subgroup.Our results support the usefulness of SR-Pyr in an individualized therapeutic regimen to improve quality of life regardless of the patient's age in myasthenia gravis.Novel AChE inhibitors with oral antisense oligonucleotides have been developed and preliminary results appear to be promising.Despite a lack of data from well controlled clinical trials to support their use, AChE inhibitors, of which pyridostigmine is the most commonly used, are recommended as first-line therapy for MG.Except for one small and inconclusive trial of intranasal neostigmine, no randomised controlled trial has been conducted on the use of acetylcholinesterase inhibitors in myasthenia gravis.", 
            "id": "5149199dd24251bc05000040", 
            "ideal_answer": [
                "Pyridostigmine and neostygmine are acetylcholinesterase inhibitors that are used as first-line therapy for symptomatic treatment of myasthenia gravis. Pyridostigmine is the most widely used acetylcholinesterase inhibitor. Extended release pyridotsygmine and novel acetylcholinesterase inhibitors inhibitors with oral antisense oligonucleotides are being studied."
            ], 
            "ranked": [
                "Acetylcholinesterase inhibitors provide temporary, symptomatic treatment for all forms of myasthenia gravis.", 
                "Pyridostigmine is the most widely used acetylcholinesterase inhibitor.", 
                "Response to acetylcholinesterase inhibitors in observational studies is so clear that a randomised controlled trial depriving participants in the placebo arm of treatment would be difficult to justify.", 
                "The switch to SR-Pyr ameliorated the total quantified myasthenia gravis (QMG) score from 0.9 \u00b1 0.5 to 0.6 \u00b1 0.4 (p<0.001) in all patients and in the younger subgroup.", 
                "Our results support the usefulness of SR-Pyr in an individualized therapeutic regimen to improve quality of life regardless of the patient's age in myasthenia gravis.", 
                "Novel AChE inhibitors with oral antisense oligonucleotides have been developed and preliminary results appear to be promising.", 
                "Despite a lack of data from well controlled clinical trials to support their use, AChE inhibitors, of which pyridostigmine is the most commonly used, are recommended as first-line therapy for MG.", 
                "Except for one small and inconclusive trial of intranasal neostigmine, no randomised controlled trial has been conducted on the use of acetylcholinesterase inhibitors in myasthenia gravis.", 
                "It is suitable as a long-term treatment in patients with generalized non-progressive milder disease, and as an adjunctive therapy in patients with severe disease who are also receiving immunotherapy.", 
                " Current guidelines and recommendations for MG treatment are based largely on clinical experience, retrospective analyses and expert consensus."
            ], 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21133188", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1251, 
                    "offsetInEndSection": 1321, 
                    "sentences": [
                        {
                            "text": "Pyridostigmine is the most widely used acetylcholinesterase inhibitor.", 
                            "tokens": [
                                "Pyridostigmine", 
                                "is", 
                                "the", 
                                "most", 
                                "widely", 
                                "used", 
                                "acetylcholinesterase", 
                                "inhibitor", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Pyridostigmine is the most widely used acetylcholinesterase inhibitor."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20663605", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 171, 
                    "sentences": [
                        {
                            "text": "For more than 50 years the acetylcholinesterase inhibitor pyridostigmine bromide has been the drug of choice in the symptomatic therapy for myasthenia gravis.", 
                            "tokens": [
                                "For", 
                                "more", 
                                "than", 
                                "50", 
                                "years", 
                                "the", 
                                "acetylcholinesterase", 
                                "inhibitor", 
                                "pyridostigmine", 
                                "bromide", 
                                "has", 
                                "been", 
                                "the", 
                                "drug", 
                                "of", 
                                "choice", 
                                "in", 
                                "the", 
                                "symptomatic", 
                                "therapy", 
                                "for", 
                                "myasthenia", 
                                "gravis", 
                                "."
                            ]
                        }
                    ], 
                    "text": "For more than 50 years the acetylcholinesterase inhibitor pyridostigmine bromide has been the drug of choice in the symptomatic therapy for myasthenia gravis. "
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20663605", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 871, 
                    "offsetInEndSection": 1229, 
                    "sentences": [
                        {
                            "text": "The switch to SR-Pyr ameliorated the total quantified myasthenia gravis (QMG) score from 0.9 \u00b1 0.5 to 0.6 \u00b1 0.4 (p<0.001) in all patients and in the younger subgroup.", 
                            "tokens": [
                                "The", 
                                "switch", 
                                "to", 
                                "SR-Pyr", 
                                "ameliorated", 
                                "the", 
                                "total", 
                                "quantified", 
                                "myasthenia", 
                                "gravis", 
                                "(", 
                                "QMG", 
                                ")", 
                                "score", 
                                "from", 
                                "0.9", 
                                "\u00b1", 
                                "0.5", 
                                "to", 
                                "0.6", 
                                "\u00b1", 
                                "0.4", 
                                "(", 
                                "p", 
                                "<", 
                                "0.001", 
                                ")", 
                                "in", 
                                "all", 
                                "patients", 
                                "and", 
                                "in", 
                                "the", 
                                "younger", 
                                "subgroup", 
                                "."
                            ]
                        }, 
                        {
                            "text": "This was accompanied by a significant improvement in the quality of life parameters.", 
                            "tokens": [
                                "This", 
                                "was", 
                                "accompanied", 
                                "by", 
                                "a", 
                                "significant", 
                                "improvement", 
                                "in", 
                                "the", 
                                "quality", 
                                "of", 
                                "life", 
                                "parameters", 
                                "."
                            ]
                        }, 
                        {
                            "text": "The health status valued by EuroQoL questionnaire improved from 0.626 \u00b1 0.286 to 0.782 \u00b1 0.186 (p<0.001).", 
                            "tokens": [
                                "The", 
                                "health", 
                                "status", 
                                "valued", 
                                "by", 
                                "EuroQoL", 
                                "questionnaire", 
                                "improved", 
                                "from", 
                                "0.626", 
                                "\u00b1", 
                                "0.286", 
                                "to", 
                                "0.782", 
                                "\u00b1", 
                                "0.186", 
                                "(", 
                                "p", 
                                "<", 
                                "0.001", 
                                ")", 
                                "."
                            ]
                        }
                    ], 
                    "text": "The switch to SR-Pyr ameliorated the total quantified myasthenia gravis (QMG) score from 0.9 \u00b1 0.5 to 0.6 \u00b1 0.4 (p<0.001) in all patients and in the younger subgroup. This was accompanied by a significant improvement in the quality of life parameters. The health status valued by EuroQoL questionnaire improved from 0.626 \u00b1 0.286 to 0.782 \u00b1 0.186 (p<0.001). "
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20663605", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1412, 
                    "offsetInEndSection": 1578, 
                    "sentences": [
                        {
                            "text": "Our results support the usefulness of SR-Pyr in an individualized therapeutic regimen to improve quality of life regardless of the patient's age in myasthenia gravis.", 
                            "tokens": [
                                "Our", 
                                "results", 
                                "support", 
                                "the", 
                                "usefulness", 
                                "of", 
                                "SR-Pyr", 
                                "in", 
                                "an", 
                                "individualized", 
                                "therapeutic", 
                                "regimen", 
                                "to", 
                                "improve", 
                                "quality", 
                                "of", 
                                "life", 
                                "regardless", 
                                "of", 
                                "the", 
                                "patient", 
                                "'s", 
                                "age", 
                                "in", 
                                "myasthenia", 
                                "gravis", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Our results support the usefulness of SR-Pyr in an individualized therapeutic regimen to improve quality of life regardless of the patient's age in myasthenia gravis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 476, 
                    "offsetInEndSection": 571, 
                    "sentences": [
                        {
                            "text": "This review focuses on treatment of MG, mainly on the use of the AChE inhibitor pyridostigmine.", 
                            "tokens": [
                                "This", 
                                "review", 
                                "focuses", 
                                "on", 
                                "treatment", 
                                "of", 
                                "MG", 
                                ",", 
                                "mainly", 
                                "on", 
                                "the", 
                                "use", 
                                "of", 
                                "the", 
                                "AChE", 
                                "inhibitor", 
                                "pyridostigmine", 
                                "."
                            ]
                        }
                    ], 
                    "text": "This review focuses on treatment of MG, mainly on the use of the AChE inhibitor pyridostigmine."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 572, 
                    "offsetInEndSection": 768, 
                    "sentences": [
                        {
                            "text": "Despite a lack of data from well controlled clinical trials to support their use, AChE inhibitors, of which pyridostigmine is the most commonly used, are recommended as first-line therapy for MG.", 
                            "tokens": [
                                "Despite", 
                                "a", 
                                "lack", 
                                "of", 
                                "data", 
                                "from", 
                                "well", 
                                "controlled", 
                                "clinical", 
                                "trials", 
                                "to", 
                                "support", 
                                "their", 
                                "use", 
                                ",", 
                                "AChE", 
                                "inhibitors", 
                                ",", 
                                "of", 
                                "which", 
                                "pyridostigmine", 
                                "is", 
                                "the", 
                                "most", 
                                "commonly", 
                                "used", 
                                ",", 
                                "are", 
                                "recommended", 
                                "as", 
                                "first-line", 
                                "therapy", 
                                "for", 
                                "MG", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Despite a lack of data from well controlled clinical trials to support their use, AChE inhibitors, of which pyridostigmine is the most commonly used, are recommended as first-line therapy for MG. "
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1071, 
                    "offsetInEndSection": 1197, 
                    "sentences": [
                        {
                            "text": "Novel AChE inhibitors with oral antisense oligonucleotides have been developed and preliminary results appear to be promising.", 
                            "tokens": [
                                "Novel", 
                                "AChE", 
                                "inhibitors", 
                                "with", 
                                "oral", 
                                "antisense", 
                                "oligonucleotides", 
                                "have", 
                                "been", 
                                "developed", 
                                "and", 
                                "preliminary", 
                                "results", 
                                "appear", 
                                "to", 
                                "be", 
                                "promising", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Novel AChE inhibitors with oral antisense oligonucleotides have been developed and preliminary results appear to be promising."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21328290", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2418, 
                    "offsetInEndSection": 2808, 
                    "sentences": [
                        {
                            "text": "Except for one small and inconclusive trial of intranasal neostigmine, no randomised controlled trial has been conducted on the use of acetylcholinesterase inhibitors in myasthenia gravis.", 
                            "tokens": [
                                "Except", 
                                "for", 
                                "one", 
                                "small", 
                                "and", 
                                "inconclusive", 
                                "trial", 
                                "of", 
                                "intranasal", 
                                "neostigmine", 
                                ",", 
                                "no", 
                                "randomised", 
                                "controlled", 
                                "trial", 
                                "has", 
                                "been", 
                                "conducted", 
                                "on", 
                                "the", 
                                "use", 
                                "of", 
                                "acetylcholinesterase", 
                                "inhibitors", 
                                "in", 
                                "myasthenia", 
                                "gravis", 
                                "."
                            ]
                        }, 
                        {
                            "text": "Response to acetylcholinesterase inhibitors in observational studies is so clear that a randomised controlled trial depriving participants in the placebo arm of treatment would be difficult to justify.", 
                            "tokens": [
                                "Response", 
                                "to", 
                                "acetylcholinesterase", 
                                "inhibitors", 
                                "in", 
                                "observational", 
                                "studies", 
                                "is", 
                                "so", 
                                "clear", 
                                "that", 
                                "a", 
                                "randomised", 
                                "controlled", 
                                "trial", 
                                "depriving", 
                                "participants", 
                                "in", 
                                "the", 
                                "placebo", 
                                "arm", 
                                "of", 
                                "treatment", 
                                "would", 
                                "be", 
                                "difficult", 
                                "to", 
                                "justify", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Except for one small and inconclusive trial of intranasal neostigmine, no randomised controlled trial has been conducted on the use of acetylcholinesterase inhibitors in myasthenia gravis. Response to acetylcholinesterase inhibitors in observational studies is so clear that a randomised controlled trial depriving participants in the placebo arm of treatment would be difficult to justify."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 178, 
                    "offsetInEndSection": 475, 
                    "sentences": [
                        {
                            "text": " Current guidelines and recommendations for MG treatment are based largely on clinical experience, retrospective analyses and expert consensus.", 
                            "tokens": [
                                "Current", 
                                "guidelines", 
                                "and", 
                                "recommendations", 
                                "for", 
                                "MG", 
                                "treatment", 
                                "are", 
                                "based", 
                                "largely", 
                                "on", 
                                "clinical", 
                                "experience", 
                                ",", 
                                "retrospective", 
                                "analyses", 
                                "and", 
                                "expert", 
                                "consensus", 
                                "."
                            ]
                        }, 
                        {
                            "text": "Available therapies include oral acetylcholinesterase (AChE) inhibitors for symptomatic treatment, and short- and long-term disease-modifying treatments.", 
                            "tokens": [
                                "Available", 
                                "therapies", 
                                "include", 
                                "oral", 
                                "acetylcholinesterase", 
                                "(", 
                                "AChE", 
                                ")", 
                                "inhibitors", 
                                "for", 
                                "symptomatic", 
                                "treatment", 
                                ",", 
                                "and", 
                                "short-", 
                                "and", 
                                "long-term", 
                                "disease-modifying", 
                                "treatments", 
                                "."
                            ]
                        }
                    ], 
                    "text": " Current guidelines and recommendations for MG treatment are based largely on clinical experience, retrospective analyses and expert consensus. Available therapies include oral acetylcholinesterase (AChE) inhibitors for symptomatic treatment, and short- and long-term disease-modifying treatments."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 768, 
                    "offsetInEndSection": 1071, 
                    "sentences": [
                        {
                            "text": "Pyridostigmine has been used as a treatment for MG for over 50 years and is generally considered safe.", 
                            "tokens": [
                                "Pyridostigmine", 
                                "has", 
                                "been", 
                                "used", 
                                "as", 
                                "a", 
                                "treatment", 
                                "for", 
                                "MG", 
                                "for", 
                                "over", 
                                "50", 
                                "years", 
                                "and", 
                                "is", 
                                "generally", 
                                "considered", 
                                "safe", 
                                "."
                            ]
                        }, 
                        {
                            "text": "It is suitable as a long-term treatment in patients with generalized non-progressive milder disease, and as an adjunctive therapy in patients with severe disease who are also receiving immunotherapy.", 
                            "tokens": [
                                "It", 
                                "is", 
                                "suitable", 
                                "as", 
                                "a", 
                                "long-term", 
                                "treatment", 
                                "in", 
                                "patients", 
                                "with", 
                                "generalized", 
                                "non-progressive", 
                                "milder", 
                                "disease", 
                                ",", 
                                "and", 
                                "as", 
                                "an", 
                                "adjunctive", 
                                "therapy", 
                                "in", 
                                "patients", 
                                "with", 
                                "severe", 
                                "disease", 
                                "who", 
                                "are", 
                                "also", 
                                "receiving", 
                                "immunotherapy", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Pyridostigmine has been used as a treatment for MG for over 50 years and is generally considered safe. It is suitable as a long-term treatment in patients with generalized non-progressive milder disease, and as an adjunctive therapy in patients with severe disease who are also receiving immunotherapy. "
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15610702", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 343, 
                    "offsetInEndSection": 452, 
                    "sentences": [
                        {
                            "text": "Acetylcholinesterase inhibitors provide temporary, symptomatic treatment for all forms of myasthenia gravis.", 
                            "tokens": [
                                "Acetylcholinesterase", 
                                "inhibitors", 
                                "provide", 
                                "temporary", 
                                ",", 
                                "symptomatic", 
                                "treatment", 
                                "for", 
                                "all", 
                                "forms", 
                                "of", 
                                "myasthenia", 
                                "gravis", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Acetylcholinesterase inhibitors provide temporary, symptomatic treatment for all forms of myasthenia gravis. "
                }
            ], 
            "tokens": [
                "Which", 
                "acetylcholinesterase", 
                "inhibitors", 
                "are", 
                "used", 
                "for", 
                "treatment", 
                "of", 
                "myasthenia", 
                "gravis", 
                "?"
            ], 
            "triples": [], 
            "type": "list"
        }, 
        {
            "body": "Has Denosumab (Prolia) been approved by FDA?", 
            "concepts": [
                "http://www.biosemantics.org/jochem#4268082"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24316116", 
                "http://www.ncbi.nlm.nih.gov/pubmed/24308016", 
                "http://www.ncbi.nlm.nih.gov/pubmed/24126422", 
                "http://www.ncbi.nlm.nih.gov/pubmed/24114694", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23956508", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23759273", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23757624", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23652187", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23367751", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22716221", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22826702", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22540167", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22074657", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21942303", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21785279", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21470540", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21208140", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21170699", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21129866", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21113693", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20811384"
            ], 
            "exact_answer": "Raloxifene and denosumab are only FDA approved for postmenopausal osteoporosis. It has been approved for clinical use by the FDA in the US and by the European Medicines Agency in Europe since June 2010 (trade name Prolia(\u2122), Amgen, Thousand Oaks, CA, USA).Alendronate, risedronate, zoledronic acid, denosumab, and teriparatide are Food and Drug Administration (FDA)-approved therapeutic options.Recently, the US FDA and the EMA approved denosumab (a fully human monoclonal antibody) to treat skeletal-related events in bone-metastatic prostate cancer.We also review the evidence supporting the FDA's approval of denosumab (bone-targeted therapy) as a treatment option for men with CRPC and bony metastases.In the 2010s to date, an additional 3 antibodies (denosumab, belimumab, ipilimumab) have been approved and one antibody-drug conjugate (brentuximab vedotin) is undergoing regulatory review and may be approved in the US by August 30, 2011. Since then, an additional six human mAbs have received FDA approval: panitumumab, golimumab, canakinumab, ustekinumab, ofatumumab and denosumab.", 
            "id": "52bf1db603868f1b06000011", 
            "ideal_answer": "Yes, Denosumab was approved by the FDA in 2010.", 
            "ranked": [
                "Raloxifene and denosumab are only FDA approved for postmenopausal osteoporosis.", 
                " It has been approved for clinical use by the FDA in the US and by the European Medicines Agency in Europe since June 2010 (trade name Prolia(\u2122), Amgen, Thousand Oaks, CA, USA).", 
                "Alendronate, risedronate, zoledronic acid, denosumab, and teriparatide are Food and Drug Administration (FDA)-approved therapeutic options.", 
                "Recently, the US FDA and the EMA approved denosumab (a fully human monoclonal antibody) to treat skeletal-related events in bone-metastatic prostate cancer.", 
                "We also review the evidence supporting the FDA's approval of denosumab (bone-targeted therapy) as a treatment option for men with CRPC and bony metastases.", 
                "In the 2010s to date, an additional 3 antibodies (denosumab, belimumab, ipilimumab) have been approved and one antibody-drug conjugate (brentuximab vedotin) is undergoing regulatory review and may be approved in the US by August 30, 2011.", 
                "On the basis of this data, the FDA approved denosumab for the treatment of patients whose GCTB is unresectable, or when surgery is likely to result in severe morbidity.", 
                " The authors present the imaging findings and technical report of an attempted percutaneous vertebroplasty in the only patient found to be actively under treatment with denosumab after a retrospective review of the databank of patients with pathological fractures referred to the Department Radiology of the Ohio State University for percutaneous vertebroplasty (a total sample of 20 patients) since the FDA approval of denosumab (November 2010) until June of 2013 (a 30-month period).", 
                "Denosumab is a RANK-ligand antibody that was approved by the FDA in 2010 for the prevention of skeletal fractures in patients with bone metastases from solid tumors.", 
                " Since then, an additional six human mAbs have received FDA approval: panitumumab, golimumab, canakinumab, ustekinumab, ofatumumab and denosumab."
            ], 
            "snippets": [
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24316116", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 177, 
                    "sentences": [
                        {
                            "text": "Denosumab is a RANK-ligand antibody that was approved by the FDA in 2010 for the prevention of skeletal fractures in patients with bone metastases from solid tumors.", 
                            "tokens": [
                                "Denosumab", 
                                "is", 
                                "a", 
                                "RANK-ligand", 
                                "antibody", 
                                "that", 
                                "was", 
                                "approved", 
                                "by", 
                                "the", 
                                "FDA", 
                                "in", 
                                "2010", 
                                "for", 
                                "the", 
                                "prevention", 
                                "of", 
                                "skeletal", 
                                "fractures", 
                                "in", 
                                "patients", 
                                "with", 
                                "bone", 
                                "metastases", 
                                "from", 
                                "solid", 
                                "tumors", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Denosumab is a RANK-ligand antibody that was approved by the FDA in 2010 for the prevention of skeletal fractures in patients with bone metastases from solid tumors."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24316116", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 776, 
                    "offsetInEndSection": 1261, 
                    "sentences": [
                        {
                            "text": " The authors present the imaging findings and technical report of an attempted percutaneous vertebroplasty in the only patient found to be actively under treatment with denosumab after a retrospective review of the databank of patients with pathological fractures referred to the Department Radiology of the Ohio State University for percutaneous vertebroplasty (a total sample of 20 patients) since the FDA approval of denosumab (November 2010) until June of 2013 (a 30-month period).", 
                            "tokens": [
                                "The", 
                                "authors", 
                                "present", 
                                "the", 
                                "imaging", 
                                "findings", 
                                "and", 
                                "technical", 
                                "report", 
                                "of", 
                                "an", 
                                "attempted", 
                                "percutaneous", 
                                "vertebroplasty", 
                                "in", 
                                "the", 
                                "only", 
                                "patient", 
                                "found", 
                                "to", 
                                "be", 
                                "actively", 
                                "under", 
                                "treatment", 
                                "with", 
                                "denosumab", 
                                "after", 
                                "a", 
                                "retrospective", 
                                "review", 
                                "of", 
                                "the", 
                                "databank", 
                                "of", 
                                "patients", 
                                "with", 
                                "pathological", 
                                "fractures", 
                                "referred", 
                                "to", 
                                "the", 
                                "Department", 
                                "Radiology", 
                                "of", 
                                "the", 
                                "Ohio", 
                                "State", 
                                "University", 
                                "for", 
                                "percutaneous", 
                                "vertebroplasty", 
                                "(", 
                                "a", 
                                "total", 
                                "sample", 
                                "of", 
                                "20", 
                                "patients", 
                                ")", 
                                "since", 
                                "the", 
                                "FDA", 
                                "approval", 
                                "of", 
                                "denosumab", 
                                "(", 
                                "November", 
                                "2010", 
                                ")", 
                                "until", 
                                "June", 
                                "of", 
                                "2013", 
                                "(", 
                                "a", 
                                "30-month", 
                                "period", 
                                ")", 
                                "."
                            ]
                        }
                    ], 
                    "text": " The authors present the imaging findings and technical report of an attempted percutaneous vertebroplasty in the only patient found to be actively under treatment with denosumab after a retrospective review of the databank of patients with pathological fractures referred to the Department Radiology of the Ohio State University for percutaneous vertebroplasty (a total sample of 20 patients) since the FDA approval of denosumab (November 2010) until June of 2013 (a 30-month period)."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24308016", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 601, 
                    "offsetInEndSection": 769, 
                    "sentences": [
                        {
                            "text": "On the basis of this data, the FDA approved denosumab for the treatment of patients whose GCTB is unresectable, or when surgery is likely to result in severe morbidity.", 
                            "tokens": [
                                "On", 
                                "the", 
                                "basis", 
                                "of", 
                                "this", 
                                "data", 
                                ",", 
                                "the", 
                                "FDA", 
                                "approved", 
                                "denosumab", 
                                "for", 
                                "the", 
                                "treatment", 
                                "of", 
                                "patients", 
                                "whose", 
                                "GCTB", 
                                "is", 
                                "unresectable", 
                                ",", 
                                "or", 
                                "when", 
                                "surgery", 
                                "is", 
                                "likely", 
                                "to", 
                                "result", 
                                "in", 
                                "severe", 
                                "morbidity", 
                                "."
                            ]
                        }
                    ], 
                    "text": "On the basis of this data, the FDA approved denosumab for the treatment of patients whose GCTB is unresectable, or when surgery is likely to result in severe morbidity."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126422", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 485, 
                    "offsetInEndSection": 816, 
                    "sentences": [
                        {
                            "text": "Denosumab (Prolia\u00ae) is a fully human monoclonal antibody for RANKL, which selectively inhibits osteoclastogenesis, being recently approved for the treatment of postmenopausal osteoporosis in women at a high or increased risk of fracture by the FDA in the United Sates and by the European Medicines Agency in Europe since June 2010.", 
                            "tokens": [
                                "Denosumab", 
                                "(", 
                                "Prolia\u00ae", 
                                ")", 
                                "is", 
                                "a", 
                                "fully", 
                                "human", 
                                "monoclonal", 
                                "antibody", 
                                "for", 
                                "RANKL", 
                                ",", 
                                "which", 
                                "selectively", 
                                "inhibits", 
                                "osteoclastogenesis", 
                                ",", 
                                "being", 
                                "recently", 
                                "approved", 
                                "for", 
                                "the", 
                                "treatment", 
                                "of", 
                                "postmenopausal", 
                                "osteoporosis", 
                                "in", 
                                "women", 
                                "at", 
                                "a", 
                                "high", 
                                "or", 
                                "increased", 
                                "risk", 
                                "of", 
                                "fracture", 
                                "by", 
                                "the", 
                                "FDA", 
                                "in", 
                                "the", 
                                "United", 
                                "Sates", 
                                "and", 
                                "by", 
                                "the", 
                                "European", 
                                "Medicines", 
                                "Agency", 
                                "in", 
                                "Europe", 
                                "since", 
                                "June", 
                                "2010", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Denosumab (Prolia\u00ae) is a fully human monoclonal antibody for RANKL, which selectively inhibits osteoclastogenesis, being recently approved for the treatment of postmenopausal osteoporosis in women at a high or increased risk of fracture by the FDA in the United Sates and by the European Medicines Agency in Europe since June 2010."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24114694", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 782, 
                    "offsetInEndSection": 999, 
                    "sentences": [
                        {
                            "text": "Recent phase II clinical trials with denosumab in skeletally mature adolescents over age 12 years and adults with GCTB, have shown both safety and efficacy, leading to its accelerated US FDA approval on 13 June 2013.", 
                            "tokens": [
                                "Recent", 
                                "phase", 
                                "II", 
                                "clinical", 
                                "trials", 
                                "with", 
                                "denosumab", 
                                "in", 
                                "skeletally", 
                                "mature", 
                                "adolescents", 
                                "over", 
                                "age", 
                                "12", 
                                "years", 
                                "and", 
                                "adults", 
                                "with", 
                                "GCTB", 
                                ",", 
                                "have", 
                                "shown", 
                                "both", 
                                "safety", 
                                "and", 
                                "efficacy", 
                                ",", 
                                "leading", 
                                "to", 
                                "its", 
                                "accelerated", 
                                "US", 
                                "FDA", 
                                "approval", 
                                "on", 
                                "13", 
                                "June", 
                                "2013", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Recent phase II clinical trials with denosumab in skeletally mature adolescents over age 12 years and adults with GCTB, have shown both safety and efficacy, leading to its accelerated US FDA approval on 13 June 2013. "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23956508", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 746, 
                    "offsetInEndSection": 1016, 
                    "sentences": [
                        {
                            "text": "Zoledronic acid (ZA), an intravenously administered bisphosphonate, and Denosumab, a subcutaneously administered inhibitor of nuclear factor B ligand (RANKL), have already been approved by Food and Drug Administration (FDA) for their use in treatment of bone metastases.", 
                            "tokens": [
                                "Zoledronic", 
                                "acid", 
                                "(", 
                                "ZA", 
                                ")", 
                                ",", 
                                "an", 
                                "intravenously", 
                                "administered", 
                                "bisphosphonate", 
                                ",", 
                                "and", 
                                "Denosumab", 
                                ",", 
                                "a", 
                                "subcutaneously", 
                                "administered", 
                                "inhibitor", 
                                "of", 
                                "nuclear", 
                                "factor", 
                                "B", 
                                "ligand", 
                                "(", 
                                "RANKL", 
                                ")", 
                                ",", 
                                "have", 
                                "already", 
                                "been", 
                                "approved", 
                                "by", 
                                "Food", 
                                "and", 
                                "Drug", 
                                "Administration", 
                                "(", 
                                "FDA", 
                                ")", 
                                "for", 
                                "their", 
                                "use", 
                                "in", 
                                "treatment", 
                                "of", 
                                "bone", 
                                "metastases", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Zoledronic acid (ZA), an intravenously administered bisphosphonate, and Denosumab, a subcutaneously administered inhibitor of nuclear factor B ligand (RANKL), have already been approved by Food and Drug Administration (FDA) for their use in treatment of bone metastases."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23759273", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 736, 
                    "offsetInEndSection": 970, 
                    "sentences": [
                        {
                            "text": "These results led to the approval of denosumab by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), for the prevention of SREs in adults with bone metastases from solid tumors, including breast cancer.", 
                            "tokens": [
                                "These", 
                                "results", 
                                "led", 
                                "to", 
                                "the", 
                                "approval", 
                                "of", 
                                "denosumab", 
                                "by", 
                                "the", 
                                "European", 
                                "Medicines", 
                                "Agency", 
                                "(", 
                                "EMA", 
                                ")", 
                                "and", 
                                "the", 
                                "US", 
                                "Food", 
                                "and", 
                                "Drug", 
                                "Administration", 
                                "(", 
                                "FDA", 
                                ")", 
                                ",", 
                                "for", 
                                "the", 
                                "prevention", 
                                "of", 
                                "SREs", 
                                "in", 
                                "adults", 
                                "with", 
                                "bone", 
                                "metastases", 
                                "from", 
                                "solid", 
                                "tumors", 
                                ",", 
                                "including", 
                                "breast", 
                                "cancer", 
                                "."
                            ]
                        }
                    ], 
                    "text": "These results led to the approval of denosumab by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), for the prevention of SREs in adults with bone metastases from solid tumors, including breast cancer."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23757624", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1070, 
                    "offsetInEndSection": 1210, 
                    "sentences": [
                        {
                            "text": "Alendronate, risedronate, zoledronic acid, denosumab, and teriparatide are Food and Drug Administration (FDA)-approved therapeutic options.", 
                            "tokens": [
                                "Alendronate", 
                                ",", 
                                "risedronate", 
                                ",", 
                                "zoledronic", 
                                "acid", 
                                ",", 
                                "denosumab", 
                                ",", 
                                "and", 
                                "teriparatide", 
                                "are", 
                                "Food", 
                                "and", 
                                "Drug", 
                                "Administration", 
                                "(", 
                                "FDA", 
                                ")", 
                                "-approved", 
                                "therapeutic", 
                                "options", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Alendronate, risedronate, zoledronic acid, denosumab, and teriparatide are Food and Drug Administration (FDA)-approved therapeutic options. "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23652187", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 997, 
                    "offsetInEndSection": 1196, 
                    "sentences": [
                        {
                            "text": "Several of these therapies have recently been approved by the FDA to treat bone cancer pain (bisphosphonates, denosumab) and others are currently being evaluated in human clinical trials (tanezumab).", 
                            "tokens": [
                                "Several", 
                                "of", 
                                "these", 
                                "therapies", 
                                "have", 
                                "recently", 
                                "been", 
                                "approved", 
                                "by", 
                                "the", 
                                "FDA", 
                                "to", 
                                "treat", 
                                "bone", 
                                "cancer", 
                                "pain", 
                                "(", 
                                "bisphosphonates", 
                                ",", 
                                "denosumab", 
                                ")", 
                                "and", 
                                "others", 
                                "are", 
                                "currently", 
                                "being", 
                                "evaluated", 
                                "in", 
                                "human", 
                                "clinical", 
                                "trials", 
                                "(", 
                                "tanezumab", 
                                ")", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Several of these therapies have recently been approved by the FDA to treat bone cancer pain (bisphosphonates, denosumab) and others are currently being evaluated in human clinical trials (tanezumab)."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23367751", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 892, 
                    "offsetInEndSection": 1086, 
                    "sentences": [
                        {
                            "text": "A fourth agent, denosumab (bone targeted therapy) was also recently approved by the FDA for patients with bone metastasis after showing a reduction in the occurrence of skeletal-related events.", 
                            "tokens": [
                                "A", 
                                "fourth", 
                                "agent", 
                                ",", 
                                "denosumab", 
                                "(", 
                                "bone", 
                                "targeted", 
                                "therapy", 
                                ")", 
                                "was", 
                                "also", 
                                "recently", 
                                "approved", 
                                "by", 
                                "the", 
                                "FDA", 
                                "for", 
                                "patients", 
                                "with", 
                                "bone", 
                                "metastasis", 
                                "after", 
                                "showing", 
                                "a", 
                                "reduction", 
                                "in", 
                                "the", 
                                "occurrence", 
                                "of", 
                                "skeletal-related", 
                                "events", 
                                "."
                            ]
                        }
                    ], 
                    "text": "A fourth agent, denosumab (bone targeted therapy) was also recently approved by the FDA for patients with bone metastasis after showing a reduction in the occurrence of skeletal-related events. "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22716221", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 530, 
                    "offsetInEndSection": 968, 
                    "sentences": [
                        {
                            "text": "AHRQ published an updated review in March 2012 that summarized the benefits and risks of osteoporosis medications in treatment and prevention of osteoporosis, including bisphosphonates (aledronate, risedronate, ibandronate, zoledronic acid), parathyroid hormone, teriparatide, calcitonin, estrogens (for prevention in postmenopausal women), selective estrogen receptor modulators (raloxifene), and denosumab(approved by the FDA in 2010).", 
                            "tokens": [
                                "AHRQ", 
                                "published", 
                                "an", 
                                "updated", 
                                "review", 
                                "in", 
                                "March", 
                                "2012", 
                                "that", 
                                "summarized", 
                                "the", 
                                "benefits", 
                                "and", 
                                "risks", 
                                "of", 
                                "osteoporosis", 
                                "medications", 
                                "in", 
                                "treatment", 
                                "and", 
                                "prevention", 
                                "of", 
                                "osteoporosis", 
                                ",", 
                                "including", 
                                "bisphosphonates", 
                                "(", 
                                "aledronate", 
                                ",", 
                                "risedronate", 
                                ",", 
                                "ibandronate", 
                                ",", 
                                "zoledronic", 
                                "acid", 
                                ")", 
                                ",", 
                                "parathyroid", 
                                "hormone", 
                                ",", 
                                "teriparatide", 
                                ",", 
                                "calcitonin", 
                                ",", 
                                "estrogens", 
                                "(", 
                                "for", 
                                "prevention", 
                                "in", 
                                "postmenopausal", 
                                "women", 
                                ")", 
                                ",", 
                                "selective", 
                                "estrogen", 
                                "receptor", 
                                "modulators", 
                                "(", 
                                "raloxifene", 
                                ")", 
                                ",", 
                                "and", 
                                "denosumab", 
                                "(", 
                                "approved", 
                                "by", 
                                "the", 
                                "FDA", 
                                "in", 
                                "2010", 
                                ")", 
                                "."
                            ]
                        }
                    ], 
                    "text": "AHRQ published an updated review in March 2012 that summarized the benefits and risks of osteoporosis medications in treatment and prevention of osteoporosis, including bisphosphonates (aledronate, risedronate, ibandronate, zoledronic acid), parathyroid hormone, teriparatide, calcitonin, estrogens (for prevention in postmenopausal women), selective estrogen receptor modulators (raloxifene), and denosumab(approved by the FDA in 2010). "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22826702", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 748, 
                    "offsetInEndSection": 1029, 
                    "sentences": [
                        {
                            "text": "Four new drugs have received U.S. Food and Drug Administration (FDA)-approval in 2010 and 2011: sipuleucel-T, an immunotherapeutic agent; cabazitaxel, a novel microtubule inhibitor; abiraterone acetate, a new androgen biosynthesis inhibitor; and denosumab, a bone-targeting agent.", 
                            "tokens": [
                                "Four", 
                                "new", 
                                "drugs", 
                                "have", 
                                "received", 
                                "U.S.", 
                                "Food", 
                                "and", 
                                "Drug", 
                                "Administration", 
                                "(", 
                                "FDA", 
                                ")", 
                                "-approval", 
                                "in", 
                                "2010", 
                                "and", 
                                "2011", 
                                ":", 
                                "sipuleucel-T", 
                                ",", 
                                "an", 
                                "immunotherapeutic", 
                                "agent", 
                                ";", 
                                "cabazitaxel", 
                                ",", 
                                "a", 
                                "novel", 
                                "microtubule", 
                                "inhibitor", 
                                ";", 
                                "abiraterone", 
                                "acetate", 
                                ",", 
                                "a", 
                                "new", 
                                "androgen", 
                                "biosynthesis", 
                                "inhibitor", 
                                ";", 
                                "and", 
                                "denosumab", 
                                ",", 
                                "a", 
                                "bone-targeting", 
                                "agent", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Four new drugs have received U.S. Food and Drug Administration (FDA)-approval in 2010 and 2011: sipuleucel-T, an immunotherapeutic agent; cabazitaxel, a novel microtubule inhibitor; abiraterone acetate, a new androgen biosynthesis inhibitor; and denosumab, a bone-targeting agent. "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22540167", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 170, 
                    "offsetInEndSection": 326, 
                    "sentences": [
                        {
                            "text": "Recently, the US FDA and the EMA approved denosumab (a fully human monoclonal antibody) to treat skeletal-related events in bone-metastatic prostate cancer.", 
                            "tokens": [
                                "Recently", 
                                ",", 
                                "the", 
                                "US", 
                                "FDA", 
                                "and", 
                                "the", 
                                "EMA", 
                                "approved", 
                                "denosumab", 
                                "(", 
                                "a", 
                                "fully", 
                                "human", 
                                "monoclonal", 
                                "antibody", 
                                ")", 
                                "to", 
                                "treat", 
                                "skeletal-related", 
                                "events", 
                                "in", 
                                "bone-metastatic", 
                                "prostate", 
                                "cancer", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Recently, the US FDA and the EMA approved denosumab (a fully human monoclonal antibody) to treat skeletal-related events in bone-metastatic prostate cancer."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22074657", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1023, 
                    "offsetInEndSection": 1260, 
                    "sentences": [
                        {
                            "text": "In addition to these new and emerging therapeutic agents, denosumab was approved for the prevention of skeletal complications in patients with bone metastases due to solid tumor malignancies, providing an alternative to zoledronic acid.", 
                            "tokens": [
                                "In", 
                                "addition", 
                                "to", 
                                "these", 
                                "new", 
                                "and", 
                                "emerging", 
                                "therapeutic", 
                                "agents", 
                                ",", 
                                "denosumab", 
                                "was", 
                                "approved", 
                                "for", 
                                "the", 
                                "prevention", 
                                "of", 
                                "skeletal", 
                                "complications", 
                                "in", 
                                "patients", 
                                "with", 
                                "bone", 
                                "metastases", 
                                "due", 
                                "to", 
                                "solid", 
                                "tumor", 
                                "malignancies", 
                                ",", 
                                "providing", 
                                "an", 
                                "alternative", 
                                "to", 
                                "zoledronic", 
                                "acid", 
                                "."
                            ]
                        }
                    ], 
                    "text": "In addition to these new and emerging therapeutic agents, denosumab was approved for the prevention of skeletal complications in patients with bone metastases due to solid tumor malignancies, providing an alternative to zoledronic acid. "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21942303", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 686, 
                    "offsetInEndSection": 798, 
                    "sentences": [
                        {
                            "text": "Recently, denosumab was FDA-approved for prevention of SREs in patients with bone metastases from solid tumors.", 
                            "tokens": [
                                "Recently", 
                                ",", 
                                "denosumab", 
                                "was", 
                                "FDA-approved", 
                                "for", 
                                "prevention", 
                                "of", 
                                "SREs", 
                                "in", 
                                "patients", 
                                "with", 
                                "bone", 
                                "metastases", 
                                "from", 
                                "solid", 
                                "tumors", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Recently, denosumab was FDA-approved for prevention of SREs in patients with bone metastases from solid tumors. "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21785279", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 366, 
                    "offsetInEndSection": 604, 
                    "sentences": [
                        {
                            "text": "In the 2010s to date, an additional 3 antibodies (denosumab, belimumab, ipilimumab) have been approved and one antibody-drug conjugate (brentuximab vedotin) is undergoing regulatory review and may be approved in the US by August 30, 2011.", 
                            "tokens": [
                                "In", 
                                "the", 
                                "2010s", 
                                "to", 
                                "date", 
                                ",", 
                                "an", 
                                "additional", 
                                "3", 
                                "antibodies", 
                                "(", 
                                "denosumab", 
                                ",", 
                                "belimumab", 
                                ",", 
                                "ipilimumab", 
                                ")", 
                                "have", 
                                "been", 
                                "approved", 
                                "and", 
                                "one", 
                                "antibody-drug", 
                                "conjugate", 
                                "(", 
                                "brentuximab", 
                                "vedotin", 
                                ")", 
                                "is", 
                                "undergoing", 
                                "regulatory", 
                                "review", 
                                "and", 
                                "may", 
                                "be", 
                                "approved", 
                                "in", 
                                "the", 
                                "US", 
                                "by", 
                                "August", 
                                "30", 
                                ",", 
                                "2011", 
                                "."
                            ]
                        }
                    ], 
                    "text": "In the 2010s to date, an additional 3 antibodies (denosumab, belimumab, ipilimumab) have been approved and one antibody-drug conjugate (brentuximab vedotin) is undergoing regulatory review and may be approved in the US by August 30, 2011."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21470540", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 406, 
                    "offsetInEndSection": 562, 
                    "sentences": [
                        {
                            "text": "We also review the evidence supporting the FDA's approval of denosumab (bone-targeted therapy) as a treatment option for men with CRPC and bony metastases.", 
                            "tokens": [
                                "We", 
                                "also", 
                                "review", 
                                "the", 
                                "evidence", 
                                "supporting", 
                                "the", 
                                "FDA", 
                                "'s", 
                                "approval", 
                                "of", 
                                "denosumab", 
                                "(", 
                                "bone-targeted", 
                                "therapy", 
                                ")", 
                                "as", 
                                "a", 
                                "treatment", 
                                "option", 
                                "for", 
                                "men", 
                                "with", 
                                "CRPC", 
                                "and", 
                                "bony", 
                                "metastases", 
                                "."
                            ]
                        }
                    ], 
                    "text": "We also review the evidence supporting the FDA's approval of denosumab (bone-targeted therapy) as a treatment option for men with CRPC and bony metastases. "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21208140", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 368, 
                    "offsetInEndSection": 546, 
                    "sentences": [
                        {
                            "text": " It has been approved for clinical use by the FDA in the US and by the European Medicines Agency in Europe since June 2010 (trade name Prolia(\u2122), Amgen, Thousand Oaks, CA, USA).", 
                            "tokens": [
                                "It", 
                                "has", 
                                "been", 
                                "approved", 
                                "for", 
                                "clinical", 
                                "use", 
                                "by", 
                                "the", 
                                "FDA", 
                                "in", 
                                "the", 
                                "US", 
                                "and", 
                                "by", 
                                "the", 
                                "European", 
                                "Medicines", 
                                "Agency", 
                                "in", 
                                "Europe", 
                                "since", 
                                "June", 
                                "2010", 
                                "(", 
                                "trade", 
                                "name", 
                                "Prolia", 
                                "(", 
                                "\u2122", 
                                ")", 
                                ",", 
                                "Amgen", 
                                ",", 
                                "Thousand", 
                                "Oaks", 
                                ",", 
                                "CA", 
                                ",", 
                                "USA", 
                                ")", 
                                "."
                            ]
                        }
                    ], 
                    "text": " It has been approved for clinical use by the FDA in the US and by the European Medicines Agency in Europe since June 2010 (trade name Prolia(\u2122), Amgen, Thousand Oaks, CA, USA). "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21170699", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 147, 
                    "offsetInEndSection": 363, 
                    "sentences": [
                        {
                            "text": "The fully human monoclonal antibody denosumab (Prolia(\u00ae)) has been recently approved by the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis.", 
                            "tokens": [
                                "The", 
                                "fully", 
                                "human", 
                                "monoclonal", 
                                "antibody", 
                                "denosumab", 
                                "(", 
                                "Prolia", 
                                "(", 
                                "\u00ae", 
                                ")", 
                                ")", 
                                "has", 
                                "been", 
                                "recently", 
                                "approved", 
                                "by", 
                                "the", 
                                "European", 
                                "Medical", 
                                "Agency", 
                                "(", 
                                "EMEA", 
                                ")", 
                                "and", 
                                "the", 
                                "Food", 
                                "and", 
                                "Drug", 
                                "Administration", 
                                "(", 
                                "FDA", 
                                ")", 
                                "for", 
                                "the", 
                                "treatment", 
                                "of", 
                                "postmenopausal", 
                                "osteoporosis", 
                                "."
                            ]
                        }
                    ], 
                    "text": "The fully human monoclonal antibody denosumab (Prolia(\u00ae)) has been recently approved by the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis. "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21129866", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 1321, 
                    "offsetInEndSection": 1400, 
                    "sentences": [
                        {
                            "text": "Raloxifene and denosumab are only FDA approved for postmenopausal osteoporosis.", 
                            "tokens": [
                                "Raloxifene", 
                                "and", 
                                "denosumab", 
                                "are", 
                                "only", 
                                "FDA", 
                                "approved", 
                                "for", 
                                "postmenopausal", 
                                "osteoporosis", 
                                "."
                            ]
                        }
                    ], 
                    "text": "Raloxifene and denosumab are only FDA approved for postmenopausal osteoporosis."
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113693", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 708, 
                    "offsetInEndSection": 936, 
                    "sentences": [
                        {
                            "text": "The new antiresorptive drug, denosumab, although FDA-approved only for postmenopausal women, has been shown in a study of men on ADT to increase bone density in spine, hip, and forearm and decrease vertebral fractures on x-ray.", 
                            "tokens": [
                                "The", 
                                "new", 
                                "antiresorptive", 
                                "drug", 
                                ",", 
                                "denosumab", 
                                ",", 
                                "although", 
                                "FDA-approved", 
                                "only", 
                                "for", 
                                "postmenopausal", 
                                "women", 
                                ",", 
                                "has", 
                                "been", 
                                "shown", 
                                "in", 
                                "a", 
                                "study", 
                                "of", 
                                "men", 
                                "on", 
                                "ADT", 
                                "to", 
                                "increase", 
                                "bone", 
                                "density", 
                                "in", 
                                "spine", 
                                ",", 
                                "hip", 
                                ",", 
                                "and", 
                                "forearm", 
                                "and", 
                                "decrease", 
                                "vertebral", 
                                "fractures", 
                                "on", 
                                "x-ray", 
                                "."
                            ]
                        }
                    ], 
                    "text": "The new antiresorptive drug, denosumab, although FDA-approved only for postmenopausal women, has been shown in a study of men on ADT to increase bone density in spine, hip, and forearm and decrease vertebral fractures on x-ray. "
                }, 
                {
                    "beginSection": "abstract", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20811384", 
                    "endSection": "abstract", 
                    "offsetInBeginSection": 519, 
                    "offsetInEndSection": 665, 
                    "sentences": [
                        {
                            "text": " Since then, an additional six human mAbs have received FDA approval: panitumumab, golimumab, canakinumab, ustekinumab, ofatumumab and denosumab.", 
                            "tokens": [
                                "Since", 
                                "then", 
                                ",", 
                                "an", 
                                "additional", 
                                "six", 
                                "human", 
                                "mAbs", 
                                "have", 
                                "received", 
                                "FDA", 
                                "approval", 
                                ":", 
                                "panitumumab", 
                                ",", 
                                "golimumab", 
                                ",", 
                                "canakinumab", 
                                ",", 
                                "ustekinumab", 
                                ",", 
                                "ofatumumab", 
                                "and", 
                                "denosumab", 
                                "."
                            ]
                        }
                    ], 
                    "text": " Since then, an additional six human mAbs have received FDA approval: panitumumab, golimumab, canakinumab, ustekinumab, ofatumumab and denosumab. "
                }
            ], 
            "tokens": [
                "Has", 
                "Denosumab", 
                "(", 
                "Prolia", 
                ")", 
                "been", 
                "approved", 
                "by", 
                "FDA", 
                "?"
            ], 
            "triples": [
                {
                    "o": "FDA Structured Product Labels", 
                    "p": "http://www.w3.org/2004/02/skos/core#note", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18043383"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17995522", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "Densosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11914653"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18043383", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18087179", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "Denosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12802315"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18084860", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A12802315", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A9373021", 
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11920279", 
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17699205", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11914653", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "DENOSUMAB", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18043383"
                }, 
                {
                    "o": "denosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11920279"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/id/C1690432", 
                    "p": "http://www.w3.org/2004/02/skos/core#broader", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C2917754"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17995522", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "Densosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11914653"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18043383", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18087179", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "Denosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12802315"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18084860", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A12802315", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A9373021", 
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11920279", 
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17699205", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11914653", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "DENOSUMAB", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18043383"
                }, 
                {
                    "o": "denosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11920279"
                }, 
                {
                    "o": "Prolia", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18043386"
                }, 
                {
                    "o": "993449", 
                    "p": "http://www.w3.org/2004/02/skos/core#notation", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17995522"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17995522", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "Densosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11914653"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18043383", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18087179", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "Denosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12802315"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18084860", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A12802315", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A9373021", 
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11920279", 
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17699205", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11914653", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "DENOSUMAB", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18043383"
                }, 
                {
                    "o": "denosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11920279"
                }, 
                {
                    "o": "CDR0000481348", 
                    "p": "http://www.w3.org/2004/02/skos/core#notation", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11914653"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17995522", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "Densosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11914653"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18043383", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18087179", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "Denosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12802315"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18084860", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A12802315", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A9373021", 
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11920279", 
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17699205", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11914653", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "DENOSUMAB", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18043383"
                }, 
                {
                    "o": "denosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11920279"
                }, 
                {
                    "o": "CDR0000481348", 
                    "p": "http://www.w3.org/2004/02/skos/core#notation", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11920279"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17995522", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "Densosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11914653"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18043383", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18087179", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "Denosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12802315"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18084860", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A12802315", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A9373021", 
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11920279", 
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17699205", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11914653", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "DENOSUMAB", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18043383"
                }, 
                {
                    "o": "denosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11920279"
                }, 
                {
                    "o": "27218", 
                    "p": "http://www.w3.org/2004/02/skos/core#notation", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18087179"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17995522", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "Densosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11914653"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18043383", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18087179", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "Denosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12802315"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18084860", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A12802315", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A9373021", 
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11920279", 
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17699205", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11914653", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "DENOSUMAB", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18043383"
                }, 
                {
                    "o": "denosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11920279"
                }, 
                {
                    "o": "RXNORM", 
                    "p": "http://www.w3.org/2004/02/skos/core#note", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17995522"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17995522", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "Densosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11914653"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18043383", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18087179", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "Denosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12802315"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A18084860", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A12802315", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A9373021", 
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11920279", 
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17699205", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11914653", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1690432"
                }, 
                {
                    "o": "DENOSUMAB", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18043383"
                }, 
                {
                    "o": "denosumab", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11920279"
                }
            ], 
            "type": "yesno"
        }
    ]
}